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ABSTRACT
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic disease
characterized by symptoms of urinary urgency, frequency, bladder pain, and chronic
pelvic pain in the absence of known pathology. Selection of appropriate treatments
depended on the severity of the patient’s symptoms and patient’s preference. This
review found that it is important for providers and patients to set realistic goals for
symptom improvement when starting a new treatment.
The purposes of this project was to 1) conduct a substantive literature review on
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral
pharmacological interventions and behavioral interventions for IC/PBS, and 3)
determine the best practice recommendation for the management of ICS/PBS in adult
women. An extensive review and analysis of literature published from 2002 through
2012 was conducted to answer the following PICOT question: In women ages 18 and
older with a diagnosis of IC/PBS, who are not pregnant (P), how do oral pharmacological
interventions (I) compare with behavioral interventions (C) Best practice for managing
IC/PBS in adult women ages 18 and older, evidenced by a decrease in IC/PBS symptoms
indicated by a reduction in the patient’s ICSI and ICPI scores from baseline or patient self
reported improvement of symptoms. (T)?
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Best practice management of IC/PBS begins by setting realistic goals with the
patient for adequate symptom control and quality of life. The literature showed that
behavioral modification and adequate coping strategies significantly improve symptoms
and quality of life for women with IC/PBS (Chaiken et al., 1993; Rothrock et al., 2003).
The literature did not support the use of amitptyline, cimetidine, or hydroxyzine for
management of symptoms of IC/PBS in women (Dimitrakov et al., 2007; Hill et al., 2008;
Unwin, 2011). RCTs and systematic reviews found that PPS significantly improved
symptoms of IC/PBS and quality of life with minimal side effects and the medication was
generally well tolerated (Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008;
Sand et al., 2008). Management of IC/PBS should focus on providing adequate relief to
the patient with the most conservative treatments possible.
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INTRODUCTION
Interstitial cystitis (IC) is a chronic disease that is characterized by symptoms of
urinary urgency, frequency, bladder pain, and chronic pelvic pain in the absence of
known pathology (Heck, 2007). Recently IC has assumed labels such as painful bladder
syndrome (PBS); this term was introduced to better describe the symptom complex that
patients with IC experience (Forrest & Moldwin, 2008). Current literature refers to the
disorder as IC/PBS to avoid any unnecessary confusion (Dell, 2007; Forrest & Moldwin,
2008; Hanno et al., 2011). The typical patient with IC/PBS is a young to middle age adult
woman who complains of bladder pain, pelvic pain, urinary frequency and urgency,
nocturia, dysuria and dyspareunia in the absence of abnormal findings on a urinalysis
(UA) or urine culture (Chaiken, Blaivas, & Blaivas, 1993; Dell, 2007). Thus, IC/PBS is
often a diagnosis of exclusion based on clinical findings once differential diagnoses such
as overactive bladder, urinary tract infection, endometriosis and chronic pelvic pain
syndrome have been ruled out (Dell, 2007; Forrest & Moldwin, 2008).
Traditionally, a cystoscopy is conducted for the diagnosis of IC/PBS. Classic
cystoscopic findings include glomerulrations of the bladder known as Hunner’s Ulcers
and bleeding. However, not all patients with IC/PBS will demonstrate these classic
findings (Chaiken et al., 1993; Hanno et al., 2011; Theoharides, 2007).
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The percentage of IC/PBS patients who have Hunner’s ulcers varies from five to
fifty percent depending on the sample population studied (Klutke & Klutke, 2008;
Rosamilia, 2005). Because cystoscopy findings among patients with IC/PBS vary, current
evidence does not support the use of cystoscopy for the diagnosis of IC/PBS (Chaiken et
al., 1993; Hanno et al., 2011; Onwude, 2009; Rosenberg & Hazzard, 2005; Theoharides,
2007). Instead, providers are encouraged to identify, assess, and monitor treatment
progress using tools such as the O’Leary-Sant interstitial cystitis symptom index (ICSI),
the interstitial cystitis problem index (ICPI) and the Pelvic Pain and Urgency/Frequency
(PUF) Patient symptom scale (Dell & Butrick, 2006; Hanno et al., 2011; Nickel et al.,
2005; Theoharides, 2007). The PUF scale is a symptom questionnaire that is validated
for use in diagnosing IC/PBS. A score between 0-35 is used in the PUF scale to rate
symptoms, the higher the score the more likely a patient is to have IC/PBS (Parsons,
2006). A score of 12 is considered by experts to be indicative of IC/PBS (Forrest &
Mishell, 2009). The O’Leary-Sant ICSI and ICPI have been validated for evaluating
symptoms and problems related to IC/PBS in the patient that has already been
diagnosed with IC/PBS, these tools are recommended for use in evaluating the
effectiveness of treatments, however its validity for use as a diagnostic tool has not
been studied (O'Leary, 1998; Theoharides, 2007). These tools are primarily based on
symptomology and do not include physical exam findings or treatment guideline
parameters.
Currently, 183 treatments have been documented in the management of IC/PBS;
no one treatment or guideline approach has been identified as the standard therapy
2

(Dell & Butrick, 2006; Onwude, 2009; Rosamilia, 2005). Therapies for IC/PBS include
oral medications, intravascular medications, physical therapy, electrical stimulation,
biofeedback, dietary modifications and surgery (Hanno et al., 2011; Rosamilia, 2005;
Theoharides, 2007). Most treatments have not been shown to significantly improve
symptoms of IC/PBS; there is no single treatment that has been found to be effective for
a majority of IC/PBS patients (Dell & Butrick, 2006; Hanno et al., 2011). Clinical trials
have studied management of IC/PBS patients with varying degrees of symptom severity
making it difficult for providers to draw conclusions and generalize results (Theoharides,
2007). Selection of appropriate treatments depends on the severity of the patient’s
symptoms and patient’s preference, it is important for providers and patients to set
realistic goals for symptom improvement when starting a new treatment (Hanno et al.,
2011; Onwude, 2009).
Because of the lack of clear guidelines to aid providers in assessing and managing
IC/PBS, it is estimated that many patients are undiagnosed, misdiagnosed, or
mismanaged for five to seven years (Forrest & Mishell, 2009; Heck, 2007). Misdiagnosis,
delayed diagnosis, and inappropriate management of IC/PBS leads to decreased quality
of life and poor outcomes for patients (Forrest & Moldwin, 2008; Heck, 2007). The first
healthcare provider that many women with symptoms of IC/PBS are cared for by is not a
specialist, but their primary care provider (Patel et al., 2008). In a survey of primary care
physicians, Clemens et al. (2010) found that many primary care physicians have
erroneous beliefs about IC/PBS, including the belief that IC is caused by a psychiatric
illness or and STD. Only 67% of physicians surveyed correctly identified the hallmark
3

symptoms of IC/PBS and commonly treated patients with NSAIDS and anticholinergics,
not recommended therapies for IC/PBS (Clemens et al., 2010). Familiarity with IC/PBS
and best practice guidelines assist healthcare providers in achieving better outcomes for
women with IC/PBS. The purposes of this project is to 1) conduct a substantive
literature review on treatment guidelines for IC/PBS, 2) analyze the literature for
comparing oral pharmacological interventions and behavioral interventions for IC/PBS,
and 3) determine the best practice recommendation for the management of ICS/PBS in
adult women, ages 18 and older.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE OF THE PROBLEM
Definition
IC/PBS is a chronic progressive disease that is characterized by a collection of
symptoms including urinary urgency, frequency and chronic pelvic pain in the absence
of other explanatory pathology (Heck, 2007). There are several definitions found in the
literature. The Society for Urodynamics and Female Urology defines IC/PBS as an
unpleasant sensation, described as pain pressure or discomfort perceived to be related
to the urinary bladder and associated with lower urinary tract symptoms of more than
six weeks duration in the absence of infection or other identifiable cause (Hanno et al.,
2011). The National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK)
developed a set of diagnostic criteria for use in clinical studies of IC/PBS. The NIDDK
criteria defines IC as the presence of glomerulations or Hunner’s ulcers on cystoscopy,
and either pain associated with the bladder or urinary urgency (Forrest & Moldwin,
2008; Hanno, 2002; Hanno et al., 2011; Onwude, 2009; Rosamilia, 2005; Theoharides,
2007). The criteria developed by the NIDDK were developed for research purposes and
are considered to be too restrictive for use as clinical diagnostic criteria because it is
believed that these criteria do not capture individuals who are in early stages of IC/PBS
(Hanno, 2002; Ibrahim, Diokno, Killinger, Carrico, & Peters, 2007; Parsons, 2002;
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Rosenberg & Hazzard, 2005). However, due to the lack of definitive diagnostic criteria
the NIDDK criteria have been used in the clinical setting (Hanno, 2002). The
International Continence Society defines PBS as the complaint of suprapubic pain
related to bladder filling, accompanied by other symptoms such as increased urinary
frequency in the absence of proven UTI or other obvious pathology (Rosamilia, 2005).
Theoharides (2007) defined IC/PBS as symptoms of pain pressure or discomfort
involving the lower abdomen and bladder relieved by voiding with urinary urgency and
frequency in the absence of a UTI or other identifiable pathology.
Diagnosis
In addition to chronic pelvic pain, urinary frequency and urgency, women
complain of nocturia, dysuria, and dyspareunia (Dell, 2007). Many of these symptoms
overlap with other disorder; because of this IC/PBS is a diagnosis of exclusion.
Differential diagnoses that must be considered include chronic pelvic pain syndrome
(CPPS), overactive bladder (OAB), urinary tract infection (UTI), irritable bowel syndrome
(IBS), endometriosis and sexually transmitted diseases (STD) (Dell, 2007; Forrest &
Moldwin, 2008).
Etiology
The exact etiology of IC/PBS is unknown but several theories have been
proposed including that the IC/PBS is caused by autoimmune breakdown, infections,
neurologic disorder, and psychological factors (Klutke & Klutke, 2008). The theory that
is most widely accepted is the multifactorial theory. This theory purports that there is
initial damage to the epithelium of the bladder which leads to increased permeability to
6

cytotoxic factors resulting in chronic inflammation of the bladder lining (Burkman, 2004;
Burrell & Hurm, 1999; Dell, 2007; Forrest & Mishell, 2009; Jamison, Dawson Timothy, &
Helfand, 2007; Klutke & Klutke, 2008; Rosamilia, 2005). The initial damage to the
glycosaminoglycan (GAG) lining of the bladder can be caused by many factors including
infection, childbirth, pelvic surgery, bladder trauma or introduction of toxins to the
bladder (Forrest & Mishell, 2009; Klutke & Klutke, 2008). The increased presence of
mast cells in the bladder of women with IC/PBS suggests infectious or autoimmune
process (Burrell & Hurm, 1999; Jamison et al., 2007). The increased permeability of the
bladder epithelium and continued exposure to toxins leads to chronic inflammation and
neurogenic upregulation contributing to chronic pain, scaring of the bladder and
decreased bladder capacity (Dell, 2007; Klutke & Klutke, 2008).
The average age of onset of IC/PBS is in the mid forties. However, about 25% of
patients diagnosed are less than thirty years of age. Recently, there have been some
reports of pediatric cases. However, there is scant literature available on pediatric
IC/PBS (Hanno, 2002; Heck, 2007). IC/PBS affects both men and women. It is estimated
that 90% of the cases of IC/PBS occur in women (Heck, 2007).
Prevalence.
The prevalence of IC/PBS in the general population is a number that researchers
have struggled to ascertain. Difficulty in assessing the prevalence of IC/PBS results from
a lack of uniform diagnostic criteria, a definitive diagnostic test, the variable
presentation of symptoms in the early stages of IC and the overlap of symptoms with
other common disorders (Ibrahim et al., 2007; Rosamilia, 2005; Rosenberg & Hazzard,
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2005). To further complicate prevalence determination of IC/PBS, researchers have
found that the prevalence varies depending on which definition of IC/PBS is used.
Forrest and Moldwin (2008) suggested that sixty percent of patients that are diagnosed
with IC/PBS by an expert clinician based on clinical presentation would be excluded from
the diagnosis based on the strict NIDDK criteria.
Several studies have been conducted to attempt to estimate the prevalence of
IC/PBS, using several different definitions of the disorder. These studies have found
various prevalence rates of IC/PBS determined by the definition of IC/PBS used in the
study design. The RAND Interstitial Cystitis Epidemiology (RICE) study, found that 2.7%
to 6.5% of women in the United States over the age of 18 met the symptom criteria for
diagnosis with IC/PBS; this translates to approximately 3.4 to 7.9 million women in the
United States (Kerr, 2009). The range of prevalence estimates found in this study are
due to the use of two definitions of IC/PBS a high-sensitivity definition to estimate the
high end and a high specificity definition to estimate the low end of the range (Kerr,
2009).
Rosenberg and Hazzard (2005) conducted a study of women seen in a primary
care office for symptoms of IC/PBS such as urgency, frequency, disuria, and pelvic pain.
They used the O’Leary-Sant IC symptom (ICSI) and problem index (ICPI) and the Pelvic
Pain and Urgency/Frequency (PUF) patient symptom scale to evaluate the prevalence of
IC/PBS among their patients. Their findings indicate that using the PUF scale 12.6% of
the patient population had IC/PBS, using the O’Leary-Sant ICSI and ICPI only 0.57% of
the population met diagnostic criteria for IC/PBS (Rosenberg & Hazzard, 2005). The
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researchers conclude that the O’Leary-Sant indices are not designed for screening for
IC/PBS but as a tool to evaluate progression of established IC/PBS. The PUF index,
validated as a screening tool for IC/PBS, has increased sensitivity to identify patients
with IC/PBS (Rosenberg & Hazzard, 2005).
Rosenberg and Hazzard (2005) estimated that the actual prevalence of IC/PBS in
women in a primary care setting was between 0.57% and 12.6%, the percentages
estimated by using the PUF scale and the ICSI and ICPI. Ibrahim, Diokno, Killinger,
Carrico and Peters (2006) conducted their own study to determine the prevalence of
IC/PBS using multiple definitions of IC/PBS. Ibrahim et al. (2006) found that using the
most restrictive definition the prevalence of IC/PBS in a community population was
3.7%; using the least restrictive definition the prevalence was 17.3%. These researchers
concluded with 95% confidence that the actual prevalence of IC/PBS in the general
population is between 3.7% and 17.3%. Using their findings, Ibrahaim et al. (2007)
generalized this data to the population of women in the United States over age 18. They
estimated that between 422,803 and 21,454,813 women are affected by IC/PBS
annually.
Costs
Estimates indicate that women with IC/PBS pay two to there times more for
direct health care cost than the average woman (Stanford, Chen, Wan, Lunacsek, &
Sand, 2008).
Successful management of IC/PBS is often difficult. Early diagnosis reduces
patient care costs, as IC/PBS is more responsive to therapy in its early stages (Parsons,
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2006). Misdiagnosis, under diagnosis, and delayed diagnosis require patients to seek
evaluations by multiple health care providers, often leading to unnecessary diagnostic
testing, surgical procedures and a decreased quality of life (Forrest & Moldwin, 2008;
Heck, 2007; Sand et al., 2008). The chronic nature of IC/PBS necessitates long-term
medical management of the disorder and permanent therapeutic regimens to minimize
symptoms and improve quality of life (Schmid et al., 2011).
Wu et al. (2006) conducted a study to estimate the average medical cost for
patients with IC/PBS in the first year after diagnosis. These researchers found that the
average patient spent $1,572 U.S. on medications in the first year of treatment and
$5,041 during the first year of diagnosis on medical services. The majority of these costs
paid for outpatient services (Wu et al., 2006). Within a year, these IC/PBS patients
spent approximately $3,320 more than the control group of patients without IC/PBS
(Wu et al., 2006). These values only reflect direct cost of medical care for IC/PBS, not
the cost of lost wages due to an inability to work. Wu et al. (2006) found that the
indirect cost of IC/PBS in lost wages averages $726 during the first year of diagnosis.
Quality of life
In addition to increased health care cost, women with IC/PBS report a decreased
quality of life (QOL). Stanford et al. (2008) found that women with IC reported a
significantly lower quality of life compared to an average woman. Studies comparing the
QOL of patients with IC/PBS to women with other chronic diseases found that women
with IC/PBS reported lower quality of life than women with rheumatoid arthritis, HTN
and chronic kidney disease on dialysis (Rosamilia, 2005; Rothrock, Lutgendorf, & Kreder,
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2003). They reported sleep deprivation and increased levels of pain, including
dyspareunia. Moreover, they reported depression, suicidal ideation, absences from
work, sexual dysfunction, poor family relationships and physical and emotional stress
(Burkman, 2004; Heck, 2007; Rosamilia, 2005; Stanford et al., 2008). In short, the
unpredictable nature of the disease and symptom flares cause debilitating pain, urgency
and frequency that restrict patients to the restroom, limiting participation in social
activities (Rothrock et al., 2003; Warren, 2007). Many women with IC/PBS experienced
anxiety and depression related to their symptoms, misdiagnosis, delayed treatment, and
medical costs (Clemens et al., 2010; Forrest & Mishell, 2009; Wu et al., 2006). Studies
found that with appropriate disease specific treatment, QOL in women with IC/PBS
significantly improved (Clemens et al., 2010; Forrest & Mishell, 2009; Sairanen et al.,
2009). Forrest and Mishell (2009) as well as Sairanen et al. (2009) recommended using
quality of life indicators to evaluate effectiveness of treatment regimens for IC/PBS.
Co-morbidities.
Women with IC/PBS often have other co-morbid medical conditions that
contribute to many of the symptoms that the experience with IC/PBS. These included
allergies, fibromyalgia, inflammatory bowel disease, high tone pelvic floor muscle
dysfunction, endometriosis, vulvodynia, chronic pelvic pain syndrome, UTI, depression
and anxiety (Hanno, 2002; Panzera, 2007; Parsons, 2006; Wu et al., 2006). Control of
co-morbid conditions can improved IC/PBS symptoms. Parsons (2006) found that over
seventy percent of patients with IC/PBS also experienced environmental allergies. One
theory regarding the etiology of IC/PBS was that damage to the lining of the bladder is
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related to an allergic response (Burrell & Hurm, 1999). Control of allergies in women
with IC/PBS improved IC/PBS symptoms. Hydroxizine was especially useful over other
antihistamines because chronic use suppressed degranulation of mast cells (Parsons,
2006). A high percentage of women with IC/PBS also experienced depression; treating
depression in women with IC/PBS with amitriptyline improved depressive symptoms
and decreased pelvic pain associated with IC/PBS (Hanno et al., 2011; Parsons, 2006;
Wu et al., 2006).
Patient outcomes.
IC/PBS is a chronic disease with no known cure; management was targeted at
relieving symptoms and maximizing quality of life (Dell & Butrick, 2006; Forrest &
Mishell, 2009; Nickel et al., 2005). Negative outcomes for women with IC/PBS were
associated with debilitating pelvic pain and urinary frequency, which progressively
worsened over time (Panzera, 2007; Rosenberg, Newman, & Page, 2007; Wu et al.,
2006). The adverse outcomes associated with IC/PBS varied and included sleep
deprivation, travel and diet restrictions, avoidance of sexual intercourse, sexual
dysfunction, poor social functioning, decreased mental health, depression, poor family
relationships and an inability to work (Ibrahim et al., 2007; Panzera, 2007; Rothrock et
al., 2003; Wu et al., 2006).
Many patients faced occupational limitations due to symptoms of IC/PBS
(Rosenberg, Newman, et al., 2007; Stanford et al., 2008). Over fifty percent of patients
with IC/PBS were unable to work full time (Hanno, 2002; Rothrock et al., 2003; Wu et
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al., 2006). Ibrahim et al. (2007) reported that patients with IC/PBS were less likely to
work full time and more likely to be disabled or unemployed.
Women with IC/PBS were more likely to be diagnosed with depression, over half
of IC/PBS patients reported depression related to urinary symptoms and sexual
dysfunction (Bogart, Suttorp, Elliott, Clemens, & Berry, 2011; Rosenberg, Newman, et
al., 2007; Rothrock et al., 2003; Wu et al., 2006). Women with IC/PBS were less likely to
seek treatment for their depression due to stigma related to talking about urinary
disorders and sexual dysfunction caused by symptoms of IC/PBS (Bogart et al., 2011;
Rosenberg, Newman, et al., 2007; Rothrock et al., 2003). Sexual dysfunction was
common among women with IC/PBS, and can took many forms including dyspareunia,
symptom flares after intercourse, decreased sexual arousal and decreased orgasm
frequency (Bogart et al., 2011). Bogart et al. (2011) found that eighty-eight percent of
women with IC/PBS reported at least one symptom of sexual dysfunction, compared to
forty-three percent of women in the general U.S. population. Sexual dysfunction led to
lack of intimacy and poor family relationships (Bogart et al., 2011; Rosenberg, Newman,
et al., 2007). Approximately, seventy percent of IC/PBS patients reported disruption in
their family relationships and responsibilities due to symptoms of IC/PBS (Rothrock et
al., 2003; Wu et al., 2006).
Purpose
The purposes of this project was to 1) conduct a substantive literature review on
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral
pharmacological interventions and behavioral interventions for IC/PBS, and 3)
13

determine the best practice recommendation for the management of ICS/PBS in adult
women.
Management of IC
Health care providers were inconsistent in diagnosis and treatment of IC/PBS,
and many did not recognize the disorder early enough in most patients to effectively
manage the disease (Forrest & Mishell, 2009; Hanno et al., 2011; Heck, 2007). The
diagnosis of IC/PBS was difficult due to the lack of specific histopathologic changes,
unpredictable flares and remissions of symptoms early in the disease progression, and
an extreme variability in presenting symptoms among patients (Dell, 2007; Hanno, 2002;
Hanno et al., 2011). It was estimated that the delay in diagnosis from onset of first
symptoms is between five and seven years (Heck, 2007; Rosamilia, 2005). Early
recognition and initiation of appropriate treatment is essential to improved QOL for
women with IC/PBS. IC/PBS was shown to respond better to available treatments if
recognized early. Many treatments have better therapeutic response if initiated during
the first two and a half years of symptom onset and response improved over the
duration of treatment (Forrest & Mishell, 2009; Forrest & Moldwin, 2008; Stanford et
al., 2008). Understanding of IC/PBS diagnosis and treatment lead to earlier recognition
and appropriate treatment and improved outcomes for women with IC/PBS.
Currently, there are over 180 different therapies identified to treat IC/PBS, both
pharmacologic and non-pharmacologic. However, a gold standard for managing IC/PBS
is lacking. Hanno et al. (2011) published the only guideline for the diagnosis and
management of IC/PBS. In their guideline, the authors recognized the limitations in the
14

available literature including poorly defined patient groups, small sample sizes, lack of
placebo controls in many studies, the likely over-estimation of efficacy, short follow-up
durations, and inconsistency with outcome measure used. These limitations created
difficulties in using RCTs for a single meta analysis (Hanno et al., 2011). Hanno et al.
(2011) made treatment recommendations based on evidence grades B and C, indicating
that there was weakness in the evidence. Current treatment of IC/PBS was aimed at
reducing symptoms to a level acceptable for the individual patient and management
must be tailored to the individual (Forrest & Moldwin, 2008; Hanno et al., 2011).
Options included oral medications, intravasicular medications, and behavioral
interventions including dietary modification and physical therapy (Forrest & Moldwin,
2008). Most researchers and experts agreed that a multimodal approach to treating
IC/PBS combining pharmacologic and non-pharmacologic management strategies,
starting with least invasive therapies, yielded the best results for women with IC/PBS
(Burrell & Hurm, 1999; Dell, 2007; Dell & Butrick, 2006; Forrest & Moldwin, 2008; Hanno
et al., 2011; Klutke & Klutke, 2008).
Pharmacologic interventions.
Elmiron or pentosan polysulfate (PPS) was the only Food and Drug
Administration (FDA) approved medication for the treatment of IC/PBS (Hanno et al.,
2011; Jamison et al., 2007; Klutke & Klutke, 2008; Rosamilia, 2005; Stanford et al., 2008).
The mechanism of action of PPS was not entirely clear, it is believed that it replaces the
surface of the GAG layer of the bladder lining and inhibits histamine release by the mast
cells, decreasing bladder irritation and pain (Klutke & Klutke, 2008; Rosamilia, 2005).
15

Other oral medications that are commonly used “off-label” to treat symptoms of IC/PBS
included; amitriptyline, antihistamines specifically hydroxazine and cimetidine,
benzodiazapines and other muscle relaxants, gabapentin, steroids, anticholinergic
medications, non-steroidal anti-inflammatory drugs (NSAIDs), and narcotic and nonnarcotic pain relievers (Burrell & Hurm, 1999; Hanno et al., 2011; Jamison et al., 2007;
Stanford et al., 2008). The intravesical instillation of dimethyl sulfoxide (DMSO) was also
FDA approved for the treatment of IC/PBS; standard treatment with DMSO was
considered six doses over a three-month period (Onwude, 2009; Stanford et al., 2008).
However, DMSO instillations must be done in a clinic setting by a trained professional
and the effect on symptom relief for IC/PBS patients was not certain (Onwude, 2009).
Behavioral interventions.
Several non-pharmacological treatments were recommended for the treatment
of symptoms related to IC/PBS. One of the most common was diet modification, many
women with IC/PBS reported that symptoms are exacerbated by certain foods it is
unclear why certain foods seem to worsen symptoms (Dell & Butrick, 2006; Rosamilia,
2005; Shorter, 2006; Warren, 2007). Foods that women commonly cited as
exacerbating IC/PBS symptoms include acidic foods, foods high in potassium, citrus,
chocolate, caffeine, spices, alcohol, carbonation, tomatoes, vinegar, and artificial
sweeteners (Dell & Butrick, 2006; Rosamilia, 2005; Shorter, 2006). Not all foods in this
list exacerbated symptoms in all women with IC/PBS. Recommendations included that
women first eliminate all foods and gradually add them back into their diet one at a
time to identify offensive foods (Warren, 2007). Other non-pharmacological therapies
16

that were shown to improve symptoms of IC/PBS include stress management, exercise,
smoking cessation, relaxation techniques, pelvic floor exercises and physical therapy,
local hot and cold compresses, bladder training, biofeedback, participation in support
groups, development of coping skills and maintaining social connections (Dell, 2007; Dell
& Butrick, 2006; Forrest & Mishell, 2009; Hanno et al., 2011; Klutke & Klutke, 2008;
Rosamilia, 2005; Warren, 2007; Webster & Brennan, 1998).
PICO Question
An extensive review and analysis of literature published from 2002 through 2012
was conducted to answer the following PICOT question: In women ages 18 and older
with a diagnosis of IC/PBS, who are not pregnant (P), how do oral pharmacological
interventions (I) compare with behavioral interventions (C) best practice for managing
IC/PBS in adult women ages 18 and older, evidenced by a decrease in IC/PBS symptoms
indicated by a reduction in the patient’s ICSI and ICPI scores from baseline or patient self
reported improvement of symptoms (T) upon diagnosis? The following table depicts
that evidence-based practice question in PICOT format.
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Table 1.1: Evidence Based Practice Clinical Question
Patient
Population
Adult women
ages 18 and
older with a
diagnosis of
IC/PBS, who are
not pregnant

Intervention
Oral
pharmacological
interventions

Comparison
Intervention
Behavioral
interventions

Outcome

Time

Best practice for
Upon
managing IC/PBS in
diagnosis
adult women ages 18
and older, evidenced
by a decrease in
IC/PBS symptoms
indicated by a
reduction in the
patient’s ICSI and ICPI
scores from baseline
or patient self
reported
improvement of
symptoms.

PICO Definitions and Descriptions
1. Adult women: any female over the age of eighteen.
2. Behavioral interventions: Modifications that a woman makes to her routine to
minimize symptoms of IC/PBS including but not limited to diet modification,
stress reduction, physical therapy, biofeedback and exercises targeted at
symptom improvement (Dell, 2007; Dell & Butrick, 2006; Forrest & Mishell,
2009; Hanno et al., 2011; Klutke & Klutke, 2008; Rosamilia, 2005; Warren, 2007;
Webster & Brennan, 1998).
3. Best practice: The use of interventions and techniques that are grounded in
research and known to promote high quality care and patient outcomes (Iowa,
2012).
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4. Diagnosis: the use of scientific or clinical methods to establish the cause and
nature of a person’s illness and functional impairment caused by the pathology
(Venes, 2005).
5. Healthcare Provider: refers to advanced practice registered nurses (APRNs),
physician’s assistants (PA), and physicians that manage the care of women in an
outpatient setting.
6. Interstitial Cystitis/Painful Bladder Syndrome: as defined by the Society for
Urodynamics and Female Urology defines IC/PBS- an unpleasant sensation,
described as pain pressure or discomfort perceived to be related to the urinary
bladder and associated with lower urinary tract symptoms of more than six
weeks duration in the absence of infection or other identifiable cause (Hanno et
al., 2011).
7. O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI): a self-administered onepage assessment of the impact of symptoms of IC/PBS on patient’s QOL. Scored
from 0 to 36, a score of 36 representing the most severe symptoms. Useful in
the evaluation of effectiveness of treatments for IC/PBS (O'Leary et al., 1998;
Theoharides, 2007).
8. O’Leary-Sant Interstitial Cystitis Problem Index (ICPI): a self-administered onepage questionnaire designed to assess how problematic IC/PBS is for a patient.
Scored from 0 to 36, a score of 36 representing the most severe symptoms.
Useful in the evaluation of effectiveness of treatments for IC/PBS (O'Leary et al.,
1998; Theoharides, 2007).
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9. Patient self-reported symptom reduction: a patient’s response to a particular
treatment evaluated with an questionnaire that has been developed by
researchers to evaluate overall improvement in IC/PBS (Anderson & Perry, 2006;
Sairanen et al., 2005).
10. Symptom Reduction: A degrease in disuria, urinary frequency and urgency, pelvic
pain and other symptoms associated with IC/PBS, indicated by a 30% reduction
in ICSI score from baseline after initiation of treatment (Sand et al., 2008).
11. Pelvic Pain and Urgency/Frequency (PUF) questionnaire: a screening tool
validated for identifying patients in a clinical setting with IC/PBS. A score of
twelve or higher is indicative of IC/PBS (Forrest & Mishell, 2009; Rosenberg,
Page, & Hazzard, 2007).
12. Pharmacological Interventions: Treatment of IC/PBS symptoms with oral or
intravesical medication. Including those FDA approved for treatment of IC/PBS
and those that have been studied for off label use for treatment IC/PBS (Dell &
Butrick, 2006; Hanno et al., 2011).
13. Symptoms of IC/PBS: urinary urgency, frequency, bladder pain, chronic pelvic
pain, bladder pain, nocturia, dysuria and dyspareunia (Chaiken et al., 1993; Dell,
2007; Hanno et al., 2011; Heck, 2007).
Summary
IC/PBS is a chronic health condition that predominantly affects adult women.
Though the exact prevalence of the disorder is unknown, it was found to affect a
significant portion of the population (Forrest & Moldwin, 2008; Ibrahim et al., 2007;
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Rosenberg & Hazzard, 2005). IC/PBS was difficult to diagnose and treat because of its
variable symptom presentation, a lack of universally accepted diagnostic criteria, and
unfamiliarity with IC/PBS by health care providers (Forrest & Mishell, 2009; Klutke &
Klutke, 2008; Patel et al., 2008). The abundance of treatment options and a lack of
standardized treatment guidelines make determining the best course of treatment
challenging for healthcare providers.
The purposes of this project was to 1) conduct a substantive literature review on
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral
pharmacological interventions and behavioral interventions for IC/PBS, and 3)
determine the best practice recommendation for the reduction of IC/PBS symptoms in
women, ages 18 and older.

21

CHAPTER 2
ANALYSIS OF THE LITERATURE
Introduction
The purposes of this project was to: 1) conduct a substantive literature review on
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral
pharmacological interventions and behavioral interventions for IC/PBS, and 3)
determine the best practice recommendation for the management of ICS/PBS in adult
women, ages 18 and older. Chapter 2 provides an overview of the database findings, a
review of the literature available on oral pharmacological interventions for IC/PBS and
behavioral interventions for IC/PBS, and an overview of the American Urological
Association (AUA) Guideline on diagnosis and treatment of IC/PBS.
Overview
An extensive search of current literature was conducted to answer the PICO
question; “in adult women ages 18 and older with a diagnosis of IC/PBS who are not
pregnant, how do oral pharmacological interventions compare with behavioral
interventions as best practice for managing IC/PBS in women over 18 upon diagnosis?”
Initially a search was conducted for pre-appraised synthesized resources through
databases such as the Cochrane database of systematic reviews, the Joanna Briggs
institute, the National Guideline Clearing House and Annual Reviews (Melnyk & Fineout-

22

Overholt, 2011; Sairanen et al., 2009; Sairanen et al., 2005)). Unfortunately, a search of
these databases yielded few useful results. One guideline on the diagnosis and
treatment of IC/PBS published by the American Urological Association Education and
Research Inc. was found. The majority of research completed on IC/PBS was in the form
of peer-reviewed journal articles and research studies.
The search was broadened to include a thorough search of available
bibliographic databases (Melnyk and Fineout-Overholt, 2011). Bibliographic databases
searched were CINHAL, Medline (OVID), PubMed-Medline, Web of Science, CSA, Health
Source: Nursing/Academic edition, Nursing Resource Center, Essential Evidence Plus,
Dissertations and Theses, and Annual Reviews (Melnyk & Fineout-Overholt, 2011). A
summary of the search results is provided in table 2.1.
In conducting the search of the literature the following search terms were used,
“interstitial cystitis”, “interstitial cystitis and management”, “interstitial cystitis and
management and adult women”, “interstitial cystitis and oral management”, interstitial
cystitis and behavior management”, “interstitial cystitis and treatment”, “interstitial
cystitis and treatment and adult women”, “interstitial cystitis and oral treatment”,
“interstitial cystitis and behavior treatment”. Searches included searches of titles,
keywords, and abstracts.
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Table 2.1 Database Findings
Database
Cochrane Library

Key Words
Interstitial cystitis

Results
3

Interstitial cystitis and
management

1

Interstitial cystitis and oral
management

1

Interstitial cystitis and
behavior management

0

Interstitial cystitis and
management and adult
women

1

2
Interstitial cystitis and
treatment
2
Interstitial cystitis and oral
treatment
0
Interstitial cystitis and
behavior treatment
1

Joanna Briggs Institute
National Guideline Clearing
House

Interstitial cystitis and
treatment and adult women
Interstitial cystitis
Interstitial cystitis

0
9

Interstitial cystitis and
management

8

Interstitial cystitis and oral
management

6

Interstitial cystitis and
behavior management

3

Interstitial cystitis and
management and adult
women

6

24

9
Interstitial cystitis and
treatment
6
Interstitial cystitis and oral
treatment
3
Interstitial cystitis and
behavior treatment
6
Interstitial cystitis and
treatment and adult women
CINHAL Plus with Full Text

Interstitial cystitis

443

Interstitial cystitis and
management

46

Interstitial cystitis and oral
management

1

Interstitial cystitis and
behavior management

1

Interstitial cystitis and
management and adult
women

0

126
Interstitial cystitis and
treatment
5
Interstitial cystitis and oral
treatment
0
Interstitial cystitis and
behavior treatment
1

Medline (OVID)

Interstitial cystitis and
treatment and adult women
Interstitial cystitis

5294

Interstitial cystitis and
management

1270

Interstitial cystitis and oral
management

0

25

Interstitial cystitis and
behavior management

2

Interstitial cystitis and
management and adult
women

47

3306
Interstitial cystitis and
treatment
888
Interstitial cystitis and oral
treatment
281
Interstitial cystitis and
behavior treatment
68
Interstitial cystitis and
treatment and adult women
16
Interstitial cystitis and adult
women and behavior
treatment
35

PubMed-Medline (with USC
links)

Interstitial cystitis and oral
treatment and adult women
Interstitial cystitis

2427

Interstitial cystitis and
management

251

Interstitial cystitis and oral
management

34

Interstitial cystitis and
behavior management

16

Interstitial cystitis and
management and adult
women

47

1551
Interstitial cystitis and
treatment
156
Interstitial cystitis and oral
treatment

26

21
Interstitial cystitis and oral
treatment and adult women
Interstitial cystitis and
behavior treatment and adult
women

15

66
Interstitial cystitis and
behavior treatment
192

Web of Science

Health Source:
Nursing/Academic Edition

Interstitial cystitis and
treatment and adult women
Interstitial cystitis

1985

Interstitial cystitis and
management

0

Interstitial cystitis and
treatment

741

Interstitial cystitis and oral
treatment

66

Interstitial cystitis and
behavior treatment

17

Interstitial cystitis and
treatment and adult women
Interstitial cystitis

15

Interstitial cystitis and
management

35

Interstitial cystitis and oral
management

0

Interstitial cystitis and
behavior management

0

Interstitial cystitis and
management and adult
women

0

219

99
Interstitial cystitis and
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treatment
4
Interstitial cystitis and oral
treatment
4
Interstitial cystitis and
behavior treatment
0

Nursing Resource Center
Essential Evidence Plus

Interstitial cystitis and
treatment and adult women
Interstitial cystitis
Interstitial cystitis

2
29

Interstitial cystitis and
management

16

Interstitial cystitis and oral
management

11

Interstitial cystitis and
behavior management

8

Interstitial cystitis and
management and adult
women

5

25
Interstitial cystitis and
treatment
13
Interstitial cystitis and oral
treatment
8
Interstitial cystitis and
behavior treatment
7

Dissertations and Theses

Interstitial cystitis and
treatment and adult women
Interstitial cystitis

287

Interstitial cystitis and
management

208

Interstitial cystitis and oral
management

127

Interstitial cystitis and
behavior management

156

28

Interstitial cystitis and
management and adult
women

153

276
Interstitial cystitis and
treatment
160
Interstitial cystitis and oral
treatment
195
Interstitial cystitis and
behavior treatment
178

Annual Reviews

Interstitial cystitis and
treatment and adult women
Interstitial cystitis
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Interstitial cystitis and
management

10

Interstitial cystitis and oral
management

5

Interstitial cystitis and
behavior management

4

Interstitial cystitis and
management and adult
women

0

5
Interstitial cystitis and
treatment
0
Interstitial cystitis and oral
treatment
0
Interstitial cystitis and
behavior treatment
0
Interstitial cystitis and
treatment and adult women
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Articles were included if they were published after 2002 to ensure that recent
literature and a sufficient quantity of quality studies was used to answer the PICOT
question; with the exception of one study that is the foundation of behavioral
interventions for IC/PBS. All articles included in this review were limited to those
published in English; however, articles from countries other than the United States were
included as long as they were available in English. Articles were limited to those that
addressed the care of adults, as the population that the PICOT question sought to
address was adult women. Articles that exclusively pertained to IC/PBS in men were
excluded because the PICOT question specifically addresses the management of IC/PBS
in women. However, studies that included both men and women could not be
excluded, as some of the findings from these studies are pertinent to the management
of IC/PBS in women. Twenty-seven articles were included in this analysis, a summary of
each of these articles can be found in the table in Appendix A.
Appraisal of the Evidence
The first priority in selecting articles was to choose articles with a high grade of
evidence and whose content most specifically addressed the PICOT question. When
choosing which articles to evaluate the hierarchy of evidence that was used to select
articles for inclusion and to evaluate those articles was the levels of evidence presented
by the Scottish Intercollegiate Guidelines Network (2011) in the guide SIGN 50, a
reproduction of this hierarchy for grading evidence is included in Appendix B. The SIGN
guide has 8 grades of evidence. Grades are as follows from lowest level of evidence to
highest: 4 expert opinions, non-systematic reviews of literature and clinical articles; 3
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non-analytical studies; 2- case control or cohort studies with high risk of bias; 2+ well
conducted case control or cohort studies with low risk of bias; 2++ high quality
systematic reviews of case control or cohort studies; 1- meta-analysis, systematic
reviews, or randomized control trials (RCTs) with high risk of bias; 1+ well conducted
meta analysis, systematic reviews or RCTs with low risk of bias; 1++ high quality meta
analysis, systematic reviews of RCTs or RCTs with very low risk of bias (SIGN, 2011). The
grade assigned to each piece of evidence is listed in the second column of the table in
Appendix A.
The American Urological Association (AUA) Guidelines for the Diagnosis of and
Treatment of Interstitial Cystitis/Bladder Pain Syndrome by Hanno et al. (2011) was
analyzed as part of this review. The Appraisal of Guidelines Research and Evaluation
(AGREE) instrument was used in the analysis of this guideline. The AGREE instrument
was used following these instructions, (AGREE, 2011) written by the AGREE
Collaboration published in their 2001 guide. Utilizing this instrument this author rated
the guideline on its performance in the following six categories: scope and purpose,
stakeholder involvement, rigor of development, clarity and presentation, applicability,
and editorial independence (AGREE Collaboration, 2001). Overall the AUA guideline
received a 71%, details of the scoring in each categories are listed in the table in
Appendix A. The major weaknesses of this guideline are inherent to the lack of available
scientific research to support the guideline and the disease process of IC/PBS. The
medical community wrote the guideline for patients and healthcare providers based on
anecdotal evidence from experts caring for patients with IC/PBS. The authors also did
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not address the cost of treatments or consider input from patients with IC/PBS. There is
also no plan for how the guidelines will be updated as new research becomes available
(Hanno et al. 2011).
Oral Pharmacological Interventions
Twelve articles addressed the use of oral pharmacological interventions for the
management of IC/PBS in adult women. Seven of these articles reviewed the use of
pentosan polysulfate (PPS) or Elmiron; the other five articles examined the use of other
oral medications to manage symptoms of IC/PBS including amitriptyline,
anticholinergics, oral contraceptives, muscle relaxants, and antihistamines.
Pentosan polysulfate.
Pentosan polysulfate (PPS) is a semi-synthetic sulfated polysaccharide that is
chemically similar to heparin, it was the only oral medication approved by the FDA for
treatment of IC/PBS (Anderson & Perry, 2006). The exact pharmacokinetics were not
understood well. However, it was documented that PPS repairs the glycosaminoglycan
(GAG) layer of the bladder epithelium reducing permeability to toxins (Anderson &
Perry, 2006). Eight articles that examined the use of PPS for management of IC/PBS
were reviewed; the majority demonstrated the highest levels of evidence (rated 1+ by
the SIGN guide) available on the management of IC/PBS.
Nickel et al. (2005) conducted a RCT on the uses of PPS for the management of
adults with IC/PBS. In a double-blind analysis of 380 adult women with IC/PBS, Nickel et
al. (2005) examined the effect of three dosages of PPS, 300mg daily, 600 mg daily, and
900mg daily. Results showed no statistically significant differences in the responses
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among the three treatment groups for dosage, but 17 to 23 percent of participants
reported relief after four weeks on PPS therapy. At the end of the thirty-two week
study, another 59 to 67 percent of the participants had statistically significant
improvement in IC/PBS symptoms even if they did not have improvement at the fourweek measurement, regardless of the dose of PPS (p < .05) (Nickel et al., 2005). A
significant limitation of this study is that there was not a placebo comparison group; all
participants were in a treatment group that received PPS in varying doses (Nickel et al.,
2005).
A RCT conducted by Sairanen et al. (2005) compared treatment of IC/PBS
symptoms with PPS and oral Cyclosporine A. This trial found that Cyclosporine A was
significantly more effective (p<0.001) at reducing micturition frequency by fifty percent
than PPS after 6 months of treatment (Sairanen et al., 2005). However, adverse events
were more common in the Cyclosporine A treatment group; 30 out of 94 patients
experienced adverse events including increased blood pressure and increased serum
creatinine. Adverse events with PPS were less common and less severe; the most
common adverse events were gastrointestinal upset, fatigue and headache (Sairanen et
al., 2005). The authors cautioned that though effective, patients treated with
Cyclosporine A for IC/PBS should be monitored closely, including regular monitoring of
blood pressure and serum creatinine measurements for renal function (Sairanen et al.,
2005).
Sairanen et al. used data from the 2005 study in a subsequent 2009 study to
compare the effects of IC/PBS treatments on quality of life. The purpose of this study
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was to evaluate the treatment effect on the quality of life (QOL) of patients with IC/PBS.
Authors surmised QOL is compromised in these patients due to the nature of the
chronic disease. There is not an established specific questionnaire for evaluating QOL
in patients with IC/PBS. However, the authors used a 30-item questionnaire developed
and validated by Cleary et al. (1995) for evaluation of QOL in patients with prostate
carcinoma (Sairanen et al., 2009). This questionnaire was a self-administered
questionnaire that evaluated the QOL categories of general health perceptions, pain,
emotional well-being, vitality, social functioning, physical capacity, and sexual interest
and functioning (Cleary, Morrissey, & Oster, 1995). A sample of 550 patients with
metastatic prostate cancer was used to validate this questionnaire. Cleary et al. (1995)
found that the estimated reliability coefficient (alpha) for the scales in each country
studied ranged from 0.82 to 0.96, with the exception of items concerning sexual interest
and functioning (alpha >0.74). Correlations between general health perception and
other QOL measures were used to determine construct validity. In all subscales, except
sexual interest and functioning, the correlation was greater than 0.30 in the predicted
direction (Cleary et al., 1995). Limitations exist in the reliability and validity of this
questionnaire when evaluating sexual aspects of QOL. Siranen et al. (2009) used this
questionnaire with the exclusion of a question addressing the issue of erectile
dysfunction because 89% of the study population was women. The scores between the
QOL categories were compared using the Wilcoxon sum test and a one-way ANOVA was
applied to calculate the similarity of baseline characteristics between all treatment
arms. There were no documented statistically significant differences in baseline
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characteristics between the Cyclosporine A and PPS groups (Sairanen et al., 2009). Both
the Cyclosporine A and PPS treatment groups saw improvement in QOL scores.
However, the Cyclosporine A therapy had a statistically significantly higher quality of life
response score than PPS therapy (p <0.001). Limitations of this study existed due to
unresearched modifications of the QOL instrument and its use in this study. Because a
QOL tool for the evaluation of patients with IC/PBS did not exist, the authors use a tool
validated for another disease. That this tool has the same reliability and validity for
evaluating QOL in patients with IC/PBS cannot be assumed. Another limitation or
concern was the use of Cyclosporine A in treatment of IC/PBS. This form of treatment
was under review and not FDA approved for the management of IC/PBS. Investigators
claimed that further studies need to be conducted to support the findings of this RCT by
Sairanen et al. (2009) before recommending the use of Cyclosporine A for management
of IC/PBS. This Finnish study concluded that while Cyclosporine A is more effective than
PPS, side effects were more common and patients must be monitored more closely
when taking Cyclosporin A, than when taking PPS (Sairanen et al., 2005).
In a secondary analysis of the RCT by Nickel et al. (2005), Nickel et al. (2008)
determined that initiation of PPS therapy within six months of diagnosis with IC/PBS
demonstrated statistically significantly improved patient outcomes as measured by
improvement in the IC symptom index (ICSI) and IC problem index (ICPI) compared to
patients who did not receive PPS until two years or more after diagnosis. The ICSI and
ICPI are each a four question self-administered questionnaire that is scored using a
Likert Scale 1-5. The ICSI is designed to capture the most important voiding and pain
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symptoms and The ICPI is designed to assess how problematic patients find these
symptoms in a clear and concise manner, (O'Leary, 1997). These two indices were
initially validated in a study that compared responses from 45 patients diagnosed with
IC/PBS and 67 volunteers who denied any voiding symptoms. Demographic
characteristics of the two groups were not significantly different, with the exception
that control subjects were more likely to have higher levels of education (O'Leary et al.,
1997). Internal consistency (Cronbach’s alpha) for the ICSI exceeded 0.85, and 0.90 for
the ICPI. Test-retest reliability exceeded 0.90 for both indices. Construct validity was
measured through correlations with two overall measures of significance of symptoms.
All but one of the correlations was statistically significant. The authors concluded that
the symptom scores for the controls had very little variance (O'Leary et al., 1997). The
ICIS and ICIP used together captured the significance of the problem from the patient’s
perspective. The indices were not intended to be used as screening tools, rather as an
adjunct in the diagnosis and in evaluation of management of patients with IC/PBS
(O'Leary et al., 1997). Nickel et al. (2008) performed a retrospective sub-analysis of 128
subjects from the previous RCT who received 300 mg a day of PPS. Subjects were
categorized into two groups as receiving early treatment or late treatment. Early
treatment was defined as treatment within 6 months of the diagnosis of IC and late
treatment was defined as treatment initiation 24 months after diagnosis with IC (Nickel
et al., 2008). An ANCOVA covariance model, including a category for time since IC
diagnosis to PPS initiation as a factor and baseline score as a covariate , was used to
compare ICSI and ICPI scores between the two treatment groups (Nickel et al., 2008).
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ICSI mean scores in the early treatment group improved by an average of 3.97 points
compared to an improvement of 2.15 points in the late treatment group (p < 0.05). ICPI
mean scores improved an average 3.94 points in the early treatment group and only
1.77 points in the late treatment group (p < .01). Authors concluded that patients with
IC/PBS benefit from earlier initiation of PPS therapy (Nickel et al., 2008). Limitations of
this study included the use of time from diagnosis to initiation of PPS to evaluate time
until initiation of treatment. This may not be representative of the duration of IC/PBS
symptoms, since many patients with IC/PBS suffer with symptoms for months to years
before diagnosis. Both the early and late treatment groups had moderate to severe
IC/PBS symptoms at baseline making it difficult to generalize findings to include patients
experiencing mild IC/PBS symptoms. The majority of patients had also received at least
one medication for IC/PBS before enrollment in the study. This may have created an
unknown bias (Nickel et al., 2008).
Sand et al. (2008) also performed a secondary analysis of the RCT conducted by
Nickel et al. (2005). Sand et al. (2008) analyzed a subset of 128 women who received
300mg of PPS a day to determine response to treatment. Women were labeled
responders to PPS therapy if a 30% reduction in ICIS score was seen at the end of the 32
week study (Sand et al., 2008). Forty-two percent of women were identified as
responders to PPS treatment. However, 70% of women studied reported that they
experienced a benefit from PPS therapy, and that relief with PPS was greater than any
treatment that they had previously tried (Sand et al., 2008). The majority of subjects
(91%) were women, 95% of these women were considered to have moderate to severe
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baseline IC symptoms. Using the criteria of a reduction of 30% or more in ICSI scores to
define patients as responders, 42% (49 patients) responded to PPS (Sand et al., 2008).
PPS treatment responders were statistically significantly more likely to have higher
ratings on the treatment satisfaction questionnaire than non-responders (p < 0.001).
Fisher’s exact two sided test and Odds ratio analysis found responders were 6.27 times
more likely to be pleased with PPS (p < 0.001), 6.17 times more likely to benefit from
PPS for IC/PBS symptoms (p < 0.001) and 2.73 times more likely to recommend PPS for
IC/PBS symptoms (p < 0.005) (Sand et al., 2008). Seventy-nine percent of responders
reported that PPS provided better relief than previous treatments (p < 0.005). Among
all subjects, 70% reported a benefit from PPS at the end of the treatment period, even if
they were not identified as responders (Sand et al., 2008). The limitations of this study
were related to the sample extracted from the original RCT. The sub-sample from the
original RCT analyzed in this study was relatively small (n=128). The majority of subjects
(91%) were women with moderate to severe IC/PBS symptoms at baseline, making it
difficult to generalize this data to a population of IC/PBS patients with mild symptoms
(Sand et al., 2008).
Dimitrakov et al. (2007) conducted a systematic review of RCTs for
pharmacologic treatment of patients with IC/PBS. The authors included 21 RCTs that
were published between 1987 and 2006 that met inclusion criteria. Articles were
excluded if they did not address treatment of IC/PBS or report global or symptomspecific outcomes, did not use RCT double blind placebo controlled design, include
patients without a diagnosis of IC/PBS, were incomplete or duplicate publications, were
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not in English, or had a sample size of less than 10 (Dimitrakov et al., 2007). A total of
1470 adults participated in the 21 RCTs; 90% of these were women (Dimitrakov et al.,
2007). Global and individual symptom improvement was reported in all of the studies
reviewed, global improvement was viewed as the common outcome across all
treatments and was usually reported as the number of patients reporting selfimprovement in each group (Dimitrakov et al., 2007). The average frequency of global
improvement was 19% among control groups and 49% among treatment groups for all
RCTs. Only trials for treatment of IC/PBS with PPS had sufficient numbers to allow a
pooled analysis of effect using a random-effects model (Dimitrakov et al., 2007). Six
RCTs and one meta-analysis addressed treatment with PPS, the pooled analysis by
Dimitrakov et al. (2007) suggested a benefit from treatment (p < .05).
In a review of research literature on PPS for treatment of IC/PBS, Anderson and
Perry (2006) found that PPS had a beneficial effect for a large portion of patients with
IC/PBS. Anderson and Perry (2006) conducted a search of medical literature published in
any language from 1980 to 2006. Studies were captured if they included patients
diagnosed with IC/PBS who received PPS. When available large, well controlled trials
with appropriate statistical methodology were preferred, however relevant
pharmacodynamic and pharmacokinetic data were also included (Anderson & Perry,
2006). According to Anderson and Perry (2006), the evidence supported the use of PPS
for management of IC/PBS. PPS was generally well tolerated, easy to use over invasive
medications, and demonstrated statistical significance in reducing pain over time.
Research showed that it is a more convenient treatment option than other FDA
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approved intravesical medications, such as DMSO that required clinical visits and were
time consuming and painful (Anderson & Perry, 2006). They also found that data from
non-comparative studies showed that PPS was effective over a 116-month period.
Patients should be advised that it may take 3 to 6 months to see full treatment effect,
and treatment may need to be continued indefinitely to maintain effect. However,
patients who have not seen efficacy of PPS in a treatment period greater than 6 months
were not likely to show statistically significant improvement in pain with PPS (Anderson
& Perry, 2006). Anderson and Perry (2006) concluded that PPS was beneficial for
improvement of overall condition and relief of pain for patients with IC/PBS but that the
degree of improvement varied among patients.
Two articles based on expert opinion by Parsons (2002 & 2006) stated that the
use of PPS was successful in the treatment of IC/PBS, but duration of treatment was
more important than dosage, Parsons also found younger patients 10 to 30 years old
had good symptom improvement over a 2 to 4 month period. Parsons (2006) noted
that PPS improved symptoms of IC/PBS by correcting the dysfunction of the GAG
bladder lining. The author noted that studies did not explore the added benefit of
treating IC/PBS with PPS in conjunction with other oral medications (Parsons, 2006).
Therefore, Parsons (2006) suggested that optimal management of IC/PBS was through a
multimodal approach that included the use of PPS.
Other oral medications.
Other medications used in the management of IC/PBS included antihistamines,
tricyclic-antidepressants (TCAs) such as amitriptyline, anticholinergics, and skeletal
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muscle relaxants (Dell & Butrick, 2006). Five articles examined the use of oral
pharmacological agents other than PPS for the management of IC/PBS.
In their systematic review of 21 RCTs for management of IC/PBS, Dimitrakov et
al. (2007) found that amitriptyline is effective therapy of IC/PBS (p < 0.05). However,
hydroxysine did not show a significant effect on symptom reduction (p >0.05). One RCT
on the use of amitriptyline to treat IC/PBS found that 15 of 24 patients had symptomatic
relief with an average dose of 75 mg daily. However, the study did not provide details
regarding the use of active or inactive placebo between groups (p < .05) (Dimitrakov et
al., 2007). Many RCTs had short duration study times, did not account for the variability
of IC/PBS symptoms over time, had inadequate blinding, small sample sizes (less than
30), or non-standardized evaluation outcomes making the determination of optimal
treatment difficult between studies. The authors concluded, based on the limitations in
the trials, that other than for PPS, there was insufficient evidence to recommend the
use of other pharmacological therapies (Dimitrakov et al., 2007). Moreover, they
concluded that thus far, trials for treatment of IC/PBS with PPS had sufficient sample
numbers to allow a pooled analysis of effect using a random-effects mode. For the
remaining treatment modalities, a pooled analysis was not attempted due to a wide
variety of designs and small sample sizes. The authors attempted to abstract data as a
standardized mean difference to produce measure of effect for each treatment trial on
a similar metric, however it was not possible to classify results as positive or negative
outcome in terms of efficacy (Dimitrakov et al., 2007).
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A cross-sectional study of 750 patients with IC/PBS investigated the medications
pH modulator Prelief, phenazopyridine and PPS use for improved symptoms (Hill, IsomBatz, Panagopoulos, Zakariasen, & Kavaler, 2008). Hill et al. (2008) surveyed patients via
a computer based Internet survey that was linked on the Interstitial Cystitis network,
national Women’s Health Network and Our Bodies Ourselves websites. Questions
included demographic data, and specific information about procedures and mediations
used to treat IC/PBS and whether patients perceived their condition as improved, not
affected, or deteriorated after treatment (Hill et al., 2008). Statistical analyses were
conducted (chi-squared tests) to compare the perceptions of each treatment group
(three treatment groups) for outcomes: improved, no effect or worse (Hill et al., 2008).
Statistically significant improvements were reported among groups for all drugs
examined (p < 0.001). Of the 52.7% (n = 395, N = 750) of individuals who were
prescribed PPS, 53.4% found that the medication improved IC/PBS symptoms, 3.8%
reported worse symptoms, and 29.9% reported no effect. Thirteen percent of patients
reported intolerable side effects with PPS (p < 0.001) (Hill et al., 2008). Other
medications that significantly improved patients’ IC/PBS symptoms include
phenazopyridine, calcium glycerophosphate (Prelief), amitriptyline, and codeine.
Vistaril, tolterodine, oxybutynin, oxybutyninXL, and diphenhydramine were reported to
have no effect on IC/PBS symptoms (p > .05) (Hill et al., 2008). Patients also found that
oral medications were better than invasive therapy for management of IC/PBS
symptoms (Hill et al., 2008).
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Schmid et al. (2011) conducted a prospective cohort study of women diagnosed
with IC/PBS to determine if their treatment algorithm based on current literature
affected sexual function, quality of life and symptoms in women with IC/PBS. Seventytwo patients diagnosed with IC/PBS based on the National Institute for Diabetes and
Digestive and Kidney Diseases (NIDDK) criteria completed the study. The NIDDK
developed criteria for clinical trials to ensure that patient populations were similar, the
criteria were strict, and included changes seen on cystoscopy as a criteria for diagnosis
(Hanno, 2002). Figure 2.1 shows the complete list of the NIDDK criteria for the diagnosis
of IC/PBS. The treatment algorithm used by Schmid et al. (2011) followed a stepwise
approach to the treatment of IC/PBS starting with oral tetracycline, progressing to
bladder instillations, and eventually neurostimulation if symptoms did not improve.
Quality of life was assessed by the King’s Health Questionnaire, a visual analogue scale
(VAS) that assessed symptom severity (Schmid et al., 2011). The King’s Health
Questionnaire was a questionnaire that determined various aspects of quality of life
such as sleep, symptom bother, physical limitations, role limitations and emotions. This
21 question self-administered questionnaire was designed and validated to assess
condition-specific quality of life of women with urinary incontinence (Kelleher, Cardozo,
Khullar, & Salvatore, 1997). The questionnaire was administered to 293 women prior to
the date of a scheduled urodynamic study, to evaluate reliability. The women were
then asked to complete the questionnaire again after the completion of these studies.
Cronbach’s alpha was greater than 0.7 in all domains of the questionnaire (Kelleher et
al., 1997). One hundred and ninety-three women who completed the King’s Health
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Questionnaire also completed the Short Form 36 questionnaire, which was validated as
a tool for measuring quality of life. A statistically significant (p < 0.01) correlation
existed between scores on the King’s Health Question and the Short Form 36 in all
domains evaluated by the Short Form 36, some domains on King’s Health Questionnaire
specifically relating to urinary symptoms are not evaluated by the Short Form 36
(Kelleher et al., 1997). A visual analogue scale (VAS) was used by Schmid et al. (2011) to
quantify the severity of symptoms. Women were asked to name their most bothersome
symptoms and apply a rating of 0 to 10 using the VAS; 0 being the least bother and 10
the worst possible bother of bladder symptoms. The authors did not elaborate on the
reliability and validity findings of the scale when used for evaluating the severity of
bladder symptom bother. A two-tailed t test compared mean scores before and after
treatment (Schmid et al., 2011). Researchers found that a stepwise approach to
management of symptoms with tetracycline, oral steroids, and antihistamines
significantly improved sexual function and quality of life in women with IC/PBS. VAS
scores for pain improved significantly after receiving treatment (p < 0.001), as did
nocturia (p < 0.01) and urinary frequency (p < 0.01) (Schmid et al., 2011). However,
urgency was not statistically significantly improved using this treatment algorithm (p >
0.09). All domains of the King’s Health Questionnaire showed significant improvement
(p < 0.001) with the exception of incontinence impact (p > 0.227) (Schmid et al., 2011).
Weaknesses of this study included the use of a VAS that was not clearly defined and not
validated for measurement of pain or symptom bother in this patient population. Study
results may not be able to be applied to a general IC/PBS population due to the
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restrictive nature of the NIDDK diagnostic criteria. In addition, using patients who had
histories of failures with other treatments might suggest that these patients may have
had more severe symptoms than the general population of IC/PBS patients.
Two reviews of available medical literature examined the use of oral medications
for the management of IC/PBS. Unwin (2011), in a review of current evidence for
Essential Evidence, concluded that treatment of IC/PBS with PPS, amitriptyline and
bladder instillation with DSMO are the cornerstones of treatment. This
recommendation was supported by level B evidence indicating that further research is
needed and that the evidence is inconsistent or of poor quality (Unwin, 2011). The
strongest evidence (level A), well conducted controlled studies, supported the use of
amitriptyline for the treatment of pain, urgency and frequency associated with IC/PBS.
Amitriptyline was considered safe and effective and best used in conjunction with PPS
and non-pharmacologic management such as bladder training, diet, counseling and
physical therapy (Unwin, 2011). In an analysis of available literature on the treatment
of IC/PBS Onwude (2009) found that there were no standardized treatment
recommendations for IC/PBS and that current RCTs offered conflicting results. The
author recommended that clinicians and patients understand that evidence on
treatment of IC/PBS is limited and that they set realistic goals for management
(Onwude, 2009).
Summary.
The most rigorous studies examined the use of PPS for treatment of IC/PBS.
Current evidence supported the use of PPS for the treatment of IC/PBS. PPS is the only
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medication that is FDA approved for treatment of IC/PBS, and is generally well tolerated
(Anderson & Perry, 2006; Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008;
Sairanen et al., 2009; Sairanen et al., 2005; Sand et al., 2008). The recommended dose
of PPS is 300mg daily divided into three 100mg doses. Nickel et al. (2005) found that
longer duration of treatment led to better outcomes. In a subsequent study, Nickel et
al. (2009) found that early initiation of treatment also improved patient outcomes. Sand
et al. (2008) used data from the RCT conducted by Nickel et al. (2005) and found that in
the majority of patients PPS was more effective than other therapies. In a pooled
analysis of 6 RCTs, Dimetrakov et al. (2007) found data to support the use of PPS in
management of IC/PBS.
Other oral medications assisted with the symptoms of IC/PBS. Sairanen et al.
(2005) found that Cyclosporine A was more effective at relieving symptoms of IC/PBS,
however the side effects associated with Cyclosporine A were significantly higher than
those associated with PPS. Other medications including phenazopyridine, calcium
glycerophosphate (Prelief), amitriptyline, and codeine were shown to help relieve
symptoms of IC/PBS taken in adjunct with PPS (Hill et al., 2008; Unwin, 2011). While
there is lower level evidence that phenazopyridine, Prelief, amitriptyline, and codeine
are effective in relieving symptoms of IC/PBS, RCTs are needed to be conducted to
demonstrate efficacy, especially for off label use for the management of IC/PBS.
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Figure 2.1: NIDDK Diagnostic Criteria from Hanno (2002)

Behavioral Interventions
A dearth of literature exists examining the effectiveness of behavioral
interventions beyond case reports, anecdotal reports, and expert opinions. Chaike,
Blaivas, and Blaivas (1993) conducted a case study of 42 women with persistent
symptoms of urinary frequency and pain that increased in intensity when voiding was
delayed and was produced by bladder filling (Chaiken et al., 1993). This study examined
the effect of behavioral therapy on urgency, frequency and pain related to IC/PBS. All of
the women in this study had tried other treatments for IC/PBS including antibiotics,
tricyclic antidepressants, muscle relaxers, anticholinergics, sedatives, intravesical
instillations and mechanical interventions such as urethral dilation and hydrodistention.
Patients noted temporary improvement from these therapies but no long-term relief
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(Chaiken et al., 1993). In their study, participants attended one 45-minute behavioral
therapy session per week for 8 to 12 weeks. An experienced therapist with training in
psychology and lower urinary tract physiology performed therapy (Chaiken et al., 1993).
Baseline values for total daytime void volumes, maximum voided volume, mean voided
volume, maximum and mean inter-voiding intervals and total number of micturitions
was recorded. Post treatment values in the same categories were determined and
patients were asked to rate their global results of therapy as markedly improved,
improved, unimproved or worse. Baseline and post treatment mean values for void
volumes, maximum voided volume, mean voided volume, maximum and mean intervoiding intervals, and total number of micturitions were compared using a t-test
(Chaiken et al., 1993). Over half of the women who participated reported that their
symptoms were improved and the average increase in interval between voids was 123
minutes (Chaiken et al., 1993). The functional bladder capacity increased in 38 of 42
patients (p < 0.01), inter-voiding interval increased in all patients by an average of 93
minutes (p < 0.01), the maximum interval increased in 38 of 42 patients (p < 0.01) and
41 patients experienced a decrease in the number of micturitions a day by an average of
9 (p<0.01) (Chaiken et al., 1993). The authors concluded that behavioral therapy was
effective in reducing symptoms associated with IC/PBS. However, therapy required a
highly motivated patient and access to a skilled therapist in order to be successful
(Chaiken et al., 1993). This study was the most rigorous scientific study to date
evaluating the effect of behavior modification of symptoms of IC/PBS. This rigor
justified its inclusion for this review, despite the date of publication.
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Chaiken et al. (1993) studied women who had failed treatment of IC/PBS with
antibiotics, tricyclic antidepressants, muscle relaxers, anticholinergics, sedatives,
intravesical instillations and mechanical interventions such as urethral dilation and
hydrodistention. Some of these treatments are still used for IC/PBS. However since the
publication of Chaiken et al.’s study, new treatments have become available, such as
PPS. Currently, there have not been well-controlled trials comparing behavioral
modification such as those examined by Chaiken et al. (1993) to current
pharmacological therapy available for IC/PBS, such as PPS. An additional weakness was
that results from this study were not able to be generalized to all women with IC/PBS.
Women included in this study completed a detailed voiding journal; 16 participants
were excluded from the results because of a failure to keep the voiding journal.
Behavioral therapy requires highly motivated patients and skilled therapist. Women
included in this study were motivated to meet all participation requirements, yet future
IC/PBS patients may not have the motivation or resources to successfully complete
behavioral therapy.
Researchers identified stress reduction as an important component of
management of IC/PBS. Increased stress levels appeared to exacerbate IC/PBS
symptoms (Hanno et al., 2011; Rosamilia, 2005; Rosenberg, Newman, et al., 2007;
Rothrock et al., 2003). A case report of 64 women with diagnosed IC/PBS, meeting the
NIDDK definition of IC/PBS, sought care at a participating clinic. They completed
questionnaires and a standardized semi-structured depression interview at scheduled
clinic appointments (Rothrock et al., 2003). Participants completed the Beck Depression
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Inventory, the Hamilton Rating Scale for Depression, and the Medical Outcome Study.
Regression models were constructed to test the relationships among coping strategies,
quality of life and depression. The Beck Depression Inventory (BDI), a 21-item
instrument that assessed the severity of depressive symptoms on a Likert scale, had
reliability and validity demonstrated in populations with chronic illness (Rothrock et al.,
2003). The BDI was studied over a 25 year period with psychiatric and non-psychiatric
samples. A meta-analysis of the BDI’s internal consistency estimated an alpha
coefficient of 0.86 for psychiatric patients and 0.81 for non-psychiatric patients (Beck,
Steer, & Carbin, 1988). Correlations between the BDI samples with clinical ratings were
high, 0.72 for psychiatric patients, and 0.60 for non-psychiatric patients. Correlations
between the BDI and the Hamilton Psychiatric Rating Scale for Depression were also
high, 0.73 for psychiatric patients and 0.74 for non-psychiatric patients. These results
indicated that the BDI reliably differentiates depression from anxiety and is reliable for
use across populations (Beck et al., 1988). The Hamilton Rating Scale for Depression
(HRSD) is a 21 item structured interview that assessed depressive symptoms over the
last week. Depressive symptoms are rated on a 0 to 2 or 0 to 4 scale for severity the
higher score indicated greater depressive symptoms (Rothrock et al., 2003).
Correlations between the BDI and HRSD were statistically significant (p < 0.001, r =0.45)
(Rothrock et al., 2003). The Medical Outcomes Study 36-Item Short Form (MOS)
assessed 8 areas of functioning: physical function, role-physical, role-emotional, bodily
pain, general health, vitality, social functioning, and mental health. A higher score
indicated a better quality of life (Rothrock et al., 2003). The MOS was validated by
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creating four groups of patients based on clinical criteria differing in severity of medical
and psychiatric conditions. Comparisons among these four clinical groups tested the
validity of the scales in detecting decrements in health status associated with chronic
medical and/or psychiatric conditions (McHorney, Ware, & Raczek, 1993). Scores
between the four patient groups were statistically significantly different (p < 0.01) in all
8 scales. Patients with serious medical conditions scored significantly lower (p < 0.01)
on all scales compared to patients with minor medical conditions (McHorney et al.,
1993). Rothrock et al. (2003) used age and symptom severity as covariates in these
models. Researchers found that age and symptom severity were not associated with
depressive symptoms or mental health. However, greater severity of symptoms were
associated with catastrophizing (HPRSD) (p < 0.05) and venting (p < 0.01) (Beck
Depression Inventory) (Rothrock et al., 2003). Seeking instrumental support was
associated with a decrease in depressive symptoms (p < 0.01). Younger age (p < 0.05)
and increased symptoms severity (p < 0.001) were significantly associated with
increased pain (Rothrock et al., 2003). Maladaptive coping strategies were associated
with higher levels of depressive symptoms and decreased quality of life in patients with
IC/PBS (Rothrock et al., 2003). Authors concluded that psychosocial interventions aimed
at increasing adaptive coping improved symptoms and quality of life for women with
IC/PBS (Rothrock et al., 2003).
Shorter (2006) in a case study and non-systematic review of literature found that
anecdotal data gathered from patients and experts demonstrated that eliminating
certain foods from the diet may decrease pain associated with IC/PBS in most patients.
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Foods commonly found to exacerbate symptoms included alcoholic beverages, coffee,
tea, carbonated beverages, tomatoes and certain spices (Shorter, 2006). Foods that
exacerbated symptoms for one woman did not exacerbate symptoms for another
woman with IC/PBS. Additionally, caution is warranted not eliminate too many foods as
that may result in a deficiency of essential nutrients (Shorter, 2006). Tettamani et al.
(2001) conducted a case control twin study examining the effects of smoking, tea and
coffee consumption on IC/PBS symptoms. The authors found that tea consumption and
smoking were positively associated with symptoms of IC/PBS (p < .05); but coffee
consumption was not associated with symptoms of IC/PBS. The association of smoking
to IC/PBS symptoms may be confounded by genetic factors (Tettamanti et al., 2011).
Disease and exposure were measured at the same time in this study; therefore,
conclusions about whether the exposure preceded or resulted from the disease were
not made.
Summary.
Strong scientific evidence for the support of using behavior modification for the
treatment of IC/PBS is lacking. A few studies showed that there were some benefits to
stress reduction, behavior modifications, improved coping mechanisms, and diet
modifications (Chaiken et al., 1993; Rothrock et al., 2003; Tettamanti et al., 2011). Most
experts agreed that there was not enough evidence to support the use of behavior
modifications alone to mange IC/PBS (Dell & Butrick, 2006; Hanno et al., 2011;
Theoharides, 2007; Unwin, 2011).
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Multimodal therapy
The majority of experts agreed that the best approach to management of IC/PBS
was through a combination on medications and behavioral therapy. Scientific studies
on the treatment of IC/PBS yielded mixed results as to the effectiveness of
pharmacological treatment versus behavioral management of IC/PBS symptoms.
Rather, urologists and other experts in management of IC/PBS recommended a
multimodal approach to therapy tailored to the individual.
Most of the evidence on multi-modal management was derived from expert
opinions. Experts indicated that management of symptoms focused on attaining an
acceptable quality of life for women with IC/PBS by treatment of the dysfunctional
bladder epithelium, associated allergies and neural upregulation (Dell & Butrick, 2006;
Quillin & Erickson, 2012). They recommended that oral medications as second line
therapy or adjunct to enhance behavioral modifications (Dell & Butrick, 2006; Forrest &
Moldwin, 2008; Quillin & Erickson, 2012). Recommended oral medications included PPS,
antihistamines such as hydroxysine, and cimetidine, TCAs like amitriptyline, analgesics,
and skeletal muscle relaxants (Dell & Butrick, 2006; Forrest & Dell, 2007; Forrest &
Mishell, 2009; Forrest & Moldwin, 2008; Rosamilia, 2005; Rosenberg, Newman, et al.,
2007). Experts recommended management of IC/PBS should begin with the most
conservative treatments, including diet modification by eliminating high potassium and
acidic foods, stress reduction, exercise, bladder training, biofeedback, and pelvic floor
muscle physical therapy if appropriate (Dell, 2007; Dell & Butrick, 2006; Forrest & Dell,
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2007; Forrest & Mishell, 2009; Forrest & Moldwin, 2008; Rosamilia, 2005; Rosenberg,
Newman, et al., 2007).
Summary.
Current research lacked studies on the effectiveness of a multimodal approach
to treatment of IC/PBS. Experts agreed that due to inconsistent results in control trials
and studies of pharmacological and behavior management of IC/PBS symptoms, the
best approach to management of IC/PBS is a combination of treatments tailored for
each patient (Dell, 2007; Dell & Butrick, 2006; Forrest & Dell, 2007; Forrest & Moldwin,
2008; Theoharides, 2007). Patient education was a key part of management of IC/PBS.
Patients should understand a)that the etiology of IC/PBS is not fully understood and b)
that IC/PBS is a chronic condition for which there is currently no cure. The goal of
treatment of IC/PBS is not complete elimination of symptoms, but to achieve a quality
of life that is acceptable for the patient (Dell & Butrick, 2006; Forrest & Moldwin, 2008;
Quillin & Erickson, 2012).
Guideline for Management of IC/PBS
Hanno et al. (2011) published the only guideline for IC/PBS. The American
Urological Association Guideline for the Diagnosis and Treatment of Interstitial
Cystitis/Bladder Pain Syndrome (AUA Guideline) is a guideline that provides direction to
clinicians and patients regarding the symptom recognition of IC/PBS, conducting
diagnostic procedures, and treatment management.
A committee of urologists, nurses and other clinicians with specific expertise on
IC/PBS developed the AUA guideline. The committee conducted a systematic review of
54

published articles relevant to the diagnosis and treatment of IC/PBS. Studies included
those published in English between 1983 and 2009 (Hanno et al., 2011). Meta-analysis
of randomized controlled trials and systematic reviews were used to analyze the
evidence. Bodies of evidence received grades of A, B or C to indicate the strength of the
evidence available for particular recommendations. Grade A were well-conducted RCTs
or very strong observational studies; grade B consisted of RCTs with some weakness of
procedure or generalizability or strong observational studies; observational studies that
are inconsistent, have small sample sizes or have other problems that confound
interpretation of data were graded level C (Hanno et al., 2011). Due to a lack of high
quality evidence on the diagnosis and overall management of IC/PBS, the diagnosis and
management portions of the algorithm provided clinical principles or expert opinion
(Hanno et al., 2011). The AUA defined a clinical principle as, “a statement about a
component of clinical care that is widely agreed upon by urologists or other clinicians for
which there may or may not be evidence in the medical literature” (Hanno et al., 2011,
p. 2163). The definition of an expert opinion was, “as a statement that is achieved by
consensus of the committee based on members clinical training, experience, knowledge
and judgment for which there is no evidence” (Hanno et al., 2011, p. 2163).
The AUA guideline provided an algorithm for diagnosis and treatment, included
in Appendix C (Hanno et al., 2011). First line treatments recommended by the AUA
guideline as clinical principles included: a) general relaxation and stress management, b)
patient education, c) self-care and behavior modification. Self-care and behavior
modification included: a) avoiding behaviors that worsen symptoms, b) avoidance of
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foods that are known bladder irritants such as citrus, c) pelvic floor muscle relaxation,
and d) bladder training (Hanno et al., 2011). The use of the oral medications PPS,
amitriptyline, cimetidine and hydroxyzine were second line treatments due to possible
minor side effects and unpredictable efficacy for individuals. This recommendation was
based on evidence graded levels B and C by the committee (Hanno et al., 2011). The
AUA Guideline stated that the use of long-term oral antibiotics is an ineffective
treatment that should not be used for IC/PBS. The level of evidence for this statement
is grade B and for this reason, it is considered a standard by the AUA. The AUA defined
a standard as a directive statement that an action should or should not be undertaken
based on Grade A or B evidence (Hanno et al., 2011). The AUA guideline also listed as a
recommendation that systemic oral long-term glucocorticoids should not be used to
manage IC/PBS (Hanno et al., 2011). The AUA defines a recommendation as, “a
directive statement that an action should or should not be undertaken based on Grade
C evidence” (Hanno et al., 2011, p. 2163). According to the AUA Guideline, the goal of
treatment of IC is to minimize symptoms and adverse events while maximizing the
quality of life for patients. No single treatment has been found that is effective for the
majority of women with IC/PBS (Hanno et al., 2011).
To appraise the AUA Guideline for quality of evidence, The Appraisal of
Guidelines Research and Evaluation (AGREE) instrument was used. The AGREE
instrument was designed to appraise the quality of patient care guidelines to determine
that the recommendations made are internally and externally valid, as well as feasible
for practice (AGREECollaboration, 2001). The AGREE instrument used 23 items in the six
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categories to determine the quality of the recommendations: scope and purpose,
stakeholder involvement, rigor of development, clarity and presentation, applicability,
and editorial independence (AGREE Collaboration, 2001). Each of the items was rated
on a 4 point scale ranging from 4 strongly agree to 1 strongly disagree. The category
score was then determined by standardizing the total as a percentage of the maximum
possible score for the category (AGREECollaboration, 2001). Each category score was
independent and were not aggregated into a single quality score, a threshold for the
category scores to determine if the guideline is “good” or “bad” was not set
(AGREECollaboration, 2001). The scores in each category for the AUA guideline were as
follows: Scope & purpose 78%, Stakeholder involvement 67%, Rigor 71%, Clarity 92%,
Applicability 11%, and Editorial independence 67% (AGREECollaboration, 2001; Hanno
et al., 2011). The lowest score for the AUA guideline was in the category of applicability.
According to the AGREE Collaboration (2001), a guideline should discuss potential
organizational barriers in applying the recommendations, the potential cost of applying
recommendations and key review criteria for monitoring and audit purposes to measure
adherence to the guideline. The AUA guideline did not address monitoring adherence
or provide criteria for audit purposes (Hanno et al., 2011). The AUA guideline did
present statistics on the current cost of IC/PBS and the burden on the patient and
medical community. The authors did not address how implementation of their
recommendations could impact the cost of treatment (Hanno et al., 2011). The
intended users of the AUA Guideline are Advanced Practice Nurses, Physician Assistants
and Physicians practicing in the areas of family practice, internal medicine, obstetrics
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and gynecology, and urology (Hanno et al., 2011). The AUA guideline did not make any
recommendations regarding: a) which treatments should be offered in primary care or
family practice, b) which would require a referral to a specialist, or c) at what point in
management of IC/PBS referral is appropriate (Hanno et al., 2011). Other weaknesses
of the AUA guideline for IC/PBS were inherent to the lack of available scientific research
to validate recommendations for the treatment of IC/PBS.
Summary
The purposes of this project are to: 1) conduct a substantive literature review on
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral
pharmacological interventions and behavioral interventions for IC/PBS, and 3)
determine the best practice recommendation for the management of ICS/PBS in adult
women, ages 18 and older. Currently many providers are unfamiliar with IC/PBS and the
appropriate best practice for managing IC/PBS in women. Women are commonly
treated with antibiotics despite negative urine cultures and a lack of response in the
past to antibiotic therapies (Clemens et al., 2010). A review of current literature and
development of best practice recommendation for management of IC/PBS in women
aids health care providers in recognizing IC/PBS early and initiating appropriate
treatments, thus decreasing unnecessary and inappropriate treatments and improving
the quality of life of women with IC/PBS (Clemens et al., 2010; Patel et al., 2008).
The scientific studies addressing the management of IC/PBS that are available to
date focused on the treatment of IC/PBS with pharmacological measures. The strongest
evidence in the form of RCTs, meta analysis, cohort studies and case studies focused on
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the treatment of IC/PBS with pharmacological medications, primarily PPS (Anderson &
Perry, 2006; Dimitrakov et al., 2007; Hill et al., 2008; Nickel et al., 2005; Nickel et al.,
2008; Sairanen et al., 2005; Sand et al., 2008). A few case studies reported the potential
benefit of behavior modification, diet and stress reduction for the management of
IC/PBS, however strong scientific evidence to support these treatments was lacking
(Chaiken et al., 1993; Rothrock et al., 2003; Tettamanti et al., 2011). Many experts
recommended managing IC/PBS with a multimodal treatment approach (Dell, 2007; Dell
& Butrick, 2006; Forrest & Dell, 2007; Forrest & Moldwin, 2008; Hanno et al., 2011;
Theoharides, 2007). There were many anecdotal cases reports and expert opinions that
supported this multimodal method of treatment. However, strong scientific evidence to
show that a multimodal approach achieved the best patient outcomes was lacking.
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CHAPTER 3
GUIDELINE
Interstitial Cystitis/Painful Bladder Syndrome is a chronic condition that affects
approximately 20 to 25 percent of non-pregnant adult women in the United States
(Burkman, 2004; Parsons, 2002). Many providers were unfamiliar with the diagnosis
and management of IC/PBS and patients suffering from the disease were undiagnosed
or misdiagnosed (Forrest & Moldwin, 2008; Heck, 2007). It was not uncommon for
women with IC/PBS to suffer with symptoms for five years or more before they recieved
the correct diagnosis and appropriate management (Heck, 2007). Early diagnosis and
management was shown to lead to better patient outcomes, better response to
available therapy and increased quality of life (Forrest & Moldwin, 2008; Parsons, 2006).
Current research showed that primary care providers are unfamiliar with the diagnosis
of IC/PBS and proper management (Clemens et al., 2010). In a survey of primary care
physicians, Clemens et al. (2010) found that many of primary care physicians had
erroneous beliefs about IC/PBS, including the belief IC/PBS was caused by a psychiatric
illness or an STD. Only 67% of the physicians surveyed correctly identified that the
hallmark symptom of IC/PBS as bladder pain or pressure (Clemens et al., 2010).
Physicians were also unfamiliar with appropriate treatment and diagnostic testing for
IC/PBS. Physicians often conducted tests for Chlamydia and gonorrhea, serum
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createnine, cervical cultures, and pelvic ultrasounds and treated patients with NSAIDS,
anticholinergics and antibiotics despite negative urine cultures and no response in the
past to antibiotic therapies (Clemens et al., 2010). Improving outcomes for women with
IC/PBS depends on improving healthcare providers’ familiarity with the disease and its
management. An evidenced based guideline outlining best practice for the
management of IC/PBS would improve outcomes for women with IC/PBS.
Literature Search
The search of current literature included a search of guideline databases to
determine what guidelines on the management of IC/PBS existed. A search of the term
“interstitial cystitis” in the National Guideline Clearinghouse (NGC) yielded eleven
results. However, only one pertained to IC/PBS, the remaining results included chronic
pelvic pain, haematuria, incontinence in women, lower UTIs, and cancer. The guideline
published by Hanno et al. (2011) was currently the most comprehensive guideline
available for the management of IC/PBS and was discussed in greater detail in chapter 2.
The algorithm from this guideline is included in Appendix D. The algorithm written by
Hanno et al. (2011) included basic management principles and several levels of
treatment, implemented in a step-wise fashion or simultaneously based on the
clinician’s assessment of the patient’s condition.
Effective management of IC/PBS depends on accurate diagnosis of the disease.
Current literature suggested that IC/PBS is diagnosed and managed in the primary care
setting (Patel et al., 2008). The purpose of the guideline published by Hanno et al. (2011)
was to provide a clinical framework for the diagnosis and treatment of IC/PBS. The
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authors acknowledged that due to a lack of high quality evidence supporting the
recommendations in this guideline, further RCTs related to diagnosis of IC/PBS were
needed to improve current practices.
Recommendation Evidence
Management of IC/PBS can be difficult and treatment and should be tailored to
each individual. IC/PBS is a chronic disease and a cure or complete relief from
symptoms is not a realistic outcome for patients at this time. Appropriate management
of IC/PBS focuses on reduction of symptoms and improvement of quality of life to a
level that is acceptable to the patient (Forrest & Mishell, 2009; Sairanen et al., 2009).
Non-Pharmacologic Management.
The AUA guideline by Hanno et al. (2011) stated that the clinical principle
treatment of IC/PBS should begin with the most conservative therapy providing
adequate control of symptoms to support an acceptable quality of life. A clinical
principle is a statement that is widely agreed upon by urologists or other clinicians for
which there may or may not be supporting evidence in the medical literature (Hanno et
al., 2011). According to the AUA guideline, a clinical principle for first line treatment
focuses on pain management, stress reduction, coping techniques, self-care practices,
and behavioral modifications that improve symptoms (Hanno et al., 2011). The RCT by
Chaiken et al. (1993) demonstrated the effective use of behavior modification for
management of symptoms of urgency, frequency and pain related to IC/PBS. Chaiken et
al (1993) found that behavior modification does significantly improve functional bladder
capacity in women (p < 0.01). The findings of Chaiken et al. (1993) were not
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corroborated by newer research because more recent studies of behavior modification
for the relief of symptoms of urgency, frequency and pain had not been conducted.
Rothrock et al. (2003) conducted a case report of 64 women with IC/PBS supporting the
statement by Hanno et al. (2011) that coping techniques improve outcomes for women
with IC/PBS. Rothrock et al. (2003) found that maladaptive coping strategies were
associated with higher levels of depressive symptoms and decreased quality of life in
patients with IC/PBS. Self-care practices to improve symptoms of IC/PBS suggested by
Hanno et al. (2011) included diet modification and avoidance of foods that are common
bladder irritants such as coffee or citrus products. In a case study and non-systematic
literature review Shorter (2006) found that diets must be individualized for each patient,
as foods that exacerbate symptoms in one woman may not increase symptom flares in
another. Foods that were commonly found to increase symptoms were alcoholic
beverages, coffee, tea, carbonated beverages, tomatoes, and some spices (Shorter,
2006). However, a case control study by Tettamani et al. (2001) did not support the
claim that coffee consumption exacerbates symptoms of IC/PBS. Tettamani et al. (2001)
found that coffee consumption was not associated with symptoms of IC/PBS; but tea
consumption and smoking were positively associated with symptoms of IC/PBS.
Research supported the recommendation by Hanno et al. (2011) that behavior
modifications and coping strategies reduce symptoms in women with IC/PBS (Chaiken,
Blaivas, & Blaivas, 1993; Rothrock, Lutgendorf, & Kreder, 2003). However, current
literature on the effect of diet on symptoms of IC/PBS was inconclusive with outcomes

63

showing varying results that are not consistent among all women with IC/PBS (Shorter,
2006; Tettamanti et al., 2011).

Pharmacological Management.
Second line therapy recommended as an option by Hanno et al. (2011), was the
use of oral medications; amitriptyline, cimetidine, hydrosyzine or pentosan polysulfate
(PPS) for the relief of symptoms associated with IC/PBS. However, administration of
these medications was shown to have variable efficacy for individuals. Their
administration was associated with minimal adverse effects. An AUA guideline option is
a non-directive statement that leaves the decision to take an action up to the individual
clinician and patient because the balance between benefits and risks or burden appears
to be relatively equal or unclear (Hanno et al., 2011).
The literature found that PPS was effective for the management of IC/PBS and
that the side effects of this medication were minimal and that in most patients PPS is
well tolerated (Anderson & Perry, 2006; Dimitrakov et al., 2007; Nickel et al., 2005;
Nickel et al., 2008; Sairanen et al., 2009; Sairanen et al., 2005; Sand et al., 2008). Nickel
et al. (2005) found that longer duration of PPS and earlier initiation of PPS therapy lead
to better patient outcomes (Nickel et al., 2005; Nickel et al., 2009). Based on these
findings initiation of PPS as therapy for IC/PBS should be a first line treatment rather
than a second line therapy as recommended by Hanno et al. (2011). The use of PPS for
the management of IC/PBS was the most extensively studied oral treatment for IC/PBS.
PPS is also the only oral medication approved by the FDA for treatment of IC/PBS
64

(Anderson & Perry, 2006). Several RCTs have examined the use of PPS in management
of IC/PBS. Nickel et al. (2005) conducted a RCT on the use of PPS for reduction of
symptoms of IC/PBS in women. These researchers found that at the end of the 32 week
study, 59 to 67 percent of participants had significant improvement in IC/PBS
symptoms, depending on the dose. A secondary analysis of this study found that
initiation of PPS within 6 months of diagnosis with IC/PBS improved ICSI scores by an
average of 3.97 points compared to an improvement of 2.15 points for women who
were started on PPS more than 6 months after diagnosis (p < 0.0472) (Nickel, Kaufman,
Zhang, Wan, & Sand, 2008). These findings supported the use of PPS for effective
management of IC/PBS symptoms in women and demonstrated that earlier initiation of
the medication led to better outcomes. In a separate secondary analysis of the RCT by
Nickel et al. (2005), Sand et al. (2008) found that 42% of women who were treated with
PPS found relief from IC/PBS symptoms. Women treated with PPS were more likely to
be pleased with PPS (p<0.0001), more likely to benefit from PPS for IC symptoms (p <
0.0001), and more likely to recommend PPS for IC symptoms (p < 0.046). These women
also felt that PPS provided better relief than previous treatments (p< 0.0038) (Sand et
al., 2008). A systematic review of RCTs published between 1987 and 2006 examined the
treatment of IC/PBS with PPS. In this review Dimitrakov et al. (2007) found, in a pooled
analysis of six RCTs and one meta-analysis, that treatment with PPS provided symptom
improvement for patients with IC/PBS with a relative risk for symptom improvement of
1.78 (Dimitrakov et al., 2007).
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The literature showed that use of the medications amitriptyline, cemetidine, and
hydroxyzine alone for management of IC/PBS was not effective (Hill et al., 2008; Unwin,
2011). However, Hanno et al. (2011) recommend the use of Amitriptyline, cimetidine,
and hydroxysine for the management of IC/PBS. Dimitrakove et al (2007), in a
systematic review of literature, concluded that there was insufficient evidence to
recommend the use of oral pharmacological therapies for the management on IC/PBS
other than PPS. A cross-sectional study of 750 patients with IC/PBS found that
symptoms of IC/PBS were significantly improved with amitriptyline, phenzopyridine,
Prelief and codeine (Hill, Isom-Batz, Panagopoulos, Zakariasen, & Kavaler, 2008). In a
literature review Unwin (2011) found that use of amitriptyline for treatment of pain,
urgency and frequency associated with IC/PBS was safe and effective. Best results in the
mnagment of IC/PBS was using amitriptyline in conjunction with PPS and nonpharmacological management (Unwin, 2011).
Hanno et al. (2011) recommended the use of cemetidine or hydrxyzine as second
line treatment for IC/PBS, however, current literature did not support the use of
cimetidine, or hydroxyzine for relief of symptoms associated with IC/PBS (Dimitrakov et
al., 2007; Unwin, 2011). Amitriptyline may be effective for relief of IC/PBS symptoms,
however, studies examining the use of amitriptyline were small and the findings varied.
PPS is the only oral medication for the management of IC/PBS that was supported by
high quality RCTs and systematic reviews.
As a fifth line approach Hanno et al. (2011) offered the option to use
Cyclosporine A for the management of IC/PBS, if other treatments had not provided
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adequate symptom control and quality of life or if the clinician and patient agreed that
symptoms required this approach. In a RCT comparing the use of PPS and oral
cyclosporine A for symptom relief in patients with IC/PBS, Sairanen et al. (2005) found
that cyclosporine A was significantly more effective the PPS (p<0.001). However,
adverse events associated with cyclosporine A administration were more common and
severe than PPS treatment including increased blood pressure and serum creatinine
(Sairanen et al., 2009; Sairanen et al., 2005). Cyclosporine A is not approved by the FDA
for the management of IC/PBS and clinicians are cautioned that if this treatment is used
for IC/PBS, the patient must be monitored closely (Sairanen et al., 2009). While
cyclosporine A may be effective, the side effects are more severe than PPS. Currently
this treatment is not approved by the FDA, therefore providers must use caution if using
this medication for the management of IC/PBS.
Best Practice Recommendations
A comprehensive review of literature published between 2002 and 2013 found
that the AUA Guideline by Hanno et al. (2011) is the most comprehensive guideline
currently available for the management of IC/PBS. Examination of this guideline and
other literature that is currently available addressing the management of IC/PBS in adult
women who are not pregnant found that the following recommendations represent the
best practice for the use of pharmacological interventions and behavioral interventions
for the improvement of IC/PBS symptoms in these women. Each recommendation is
given a grade based on the quality and amount of evidence available to support the
recommendation. The Scottish Intercollegiate Guidelines Network (2011) grades of
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recommendations were used to grade the evidence. Grades of A through D were given;
a grade of an A represents the strongest supporting evidence while D is based on expert
opinions. A detailed explanation of each letter grade can be found in appendix D (SIGN,
2011).
•

Behavioral modification and adequate coping strategies should be first line
therapy (Chaiken et al., 1993; Hanno et al., 2011; Rothrock et al., 2003). Hanno
et al. (2011) addressed the use of general relaxation, stress management, pain
management, self-care and behavior modification as first line treatment;
however the authors did not specifically recommend the benefit of learning
adequate coping strategies that was found to be effective by Rothrock et al.
(2003). Grade C

•

Diet modification as part of behavioral modification was not effective. Current
literature on the effect of diet on symptoms of IC/PBS was inconclusive with
outcomes showing varying results that are not consistent among all women with
IC/PBS (Shorter, 2006; Tettamanti et al., 2011). Dietary restrictions were
recommended by Hanno et al. (2011) as part of first line therapy, however
restrictions increased some patients’ stress levels without providing significant
relief (Shorter, 2006; Tettamanti et al., 2011). Grade C

•

PPS should be offered as a first line therapy for women with IC/PBS (Anderson &
Perry, 2006; Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008;
Sairanen et al., 2009; Sairanen et al., 2005; Sand et al., 2008). Hanno et al.
(2011) included PPS with all other oral medications as second line therapy due to
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the potential for minor side effects. However, the literature found that PPS was
effective for the management of IC/PBS and that the side effects of this
medication were minimal. Most patients tolerated PPS well (Anderson & Perry,
2006; Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008; Sairanen et
al., 2009; Sairanen et al., 2005; Sand et al., 2008). Nickel et al. (2005) found that
longer duration of PPS and earlier initiation of PPS therapy led to better patient
outcomes (Nickel et al., 2005; Nickel et al., 2009). Grade A
•

Amitriptyline, Cemetidine and hydroxyzine should not be used alone for the
management of IC/PBS. In conjunction with PPS, these may be offered as a
second line therapy (Dimitrakov et al., 2007; Hill et al., 2008; Unwin, 2011).
Hanno et al. (2011) grouped all oral medications together as second line therapy,
these medications should be second line therapy not only due to potential
adverse effects but also due to varied effectiveness found in the literature
(Dimitrakov et al., 2007). The literature showed that use of the medications
amitriptyline, cemetidine, and hydroxyzine alone for management of IC/PBS was
not effective, however, use of these medications with PPS showed some benefit
(Hill et al., 2008; Unwin, 2011). Grade D

•

Cyclosporin A is not recommended for the management of IC/PBS (Sairanen et
al., 2009; Sairanen et al., 2005). Hanno et al. (2011) recommended Cyclosporine
A as a fifth line treatment with an evidence grade of C. However, the adverse
events associated with Cyclosporine A administration were more common and
severe than PPS treatment. Adverse events included increased blood pressure
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and serum creatinine (Sairanen et al., 2009; Sairanen et al., 2005). Cyclosporine
A was not approved by the FDA for the management of IC/PBS and clinicians
were cautioned that if this treatment is used for IC/PBS, the patient must be
monitored closely (Sairanen et al., 2009). Grade A
Summary
Management of IC/PBS is challenging and patient care should focus on providing
adequate relief to the patient with the most conservative treatments possible. The
literature showed that behavioral modification and adequate coping strategies
significantly improve symptoms and quality of life for women with IC/PBS (Chaiken et
al., 1993; Rothrock et al., 2003). While several oral medications were suggested for the
management of IC/PBS, the literature did not show that amitptyline, cimetidine, or
hydroxyzine significantly improved symptoms of IC/PBS in women; nor improved the
quality of life in these patients (Dimitrakov et al., 2007; Hill et al., 2008; Unwin, 2011).
PPS is the only oral medication with the FDA indication for treatment of IC/PBS. RCTs
and systematic reviews found that PPS significantly improved symptoms of IC/PBS and
quality of life with minimal side effects and the medication was generally well tolerated
(Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008; Sand et al., 2008). Oral
cyclosporine A was effective in the relief of symptoms of IC/PBS, however, the side
effects of the medication were common and the risk may out weigh the benefit
(Sairanen et al., 2009; Sairanen et al., 2005). Best practice management of IC/PBS
begins by setting realistic goals with the patient for adequate symptom control and
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quality of life. Behavior modifications and coping strategies should be initiated first
then the use of PPS for symptom relief should be considered.
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CHAPTER 4
CONCLUSIONS AND RECOMMENDATIONS
This chapter will present recommendations for practice, research, leadership,
and policy development for the management of IC/PBS in women. This project has
identified best practice recommendations for management of IC/PBS based on a
comprehensive systematic review of the available literature. Implications of these
recommendations to promote evidence–based practice for the management of IC/PBS
could benefit healthcare providers and women with IC/PBS.
Implications for Practice
Currently healthcare providers do not recognize IC/PBS when women initially
present with symptoms. The diagnosis of IC/PBS is difficult due to the lack of specific
histopathologic changes, unpredictable flares and remissions of symptoms early in the
disease progression, and an extreme variability in presenting symptoms among patients
(Dell, 2007; Hanno, 2002; Hanno et al., 2011). A survey conducted by Clemens et al.
(2010) found that primary care physicians were unfamiliar with IC/PBS and many had
erroneous beliefs about the disease. Only 61% of primary care physicians surveyed
correctly understood that IC/PBS was not caused by a psychiatric illness and only 67%
identified bladder pain or pressure as the hallmark symptom of IC/PBS (Clemens et al.,
2010). This survey also found that many physicians are treating patients with IC/PBS
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with treatments proven to be ineffective; 33% of primary care providers treated their
patients with antibiotics despite negative urine cultures and a lack of response to this
treatment (Clemens et al., 2010).
It was estimated that the delay in diagnosis from onset of first symptoms is
about five years (Heck, 2007). Misdiagnosis and delayed diagnosis leads to unnecessary
diagnostic testing, surgical procedures and a decreased quality of life (Forrest &
Moldwin, 2008; Heck, 2007). Earlier recognition and appropriate treatment reduce the
negative effects of IC/PBS.
The American Association of Colleges of Nursing (AACN) defined one of the
essentials of the advanced practice nurse with a Doctorate in Nursing Practice (DNP) as
a strong scientific underpinning for practice (AACN, 2006). A DNP nurse develops a wide
knowledge base gleaned from the sciences and the ability to translate that knowledge
quickly and effectively into practice for the benefit of patients (AACN, 2006). The
advance practice nurse with a DNP has the unique skill set to translate into practice the
current research for the best management of women with IC/PBS. In collaboration with
other healthcare providers, the DNP nurse needs to implement the management
techniques proven in literature to benefit women with IC/PBS, such as oral PPS and
stress management techniques; and discontinue outdated and ineffective treatments
such as oral antibiotics and other medications shown to be ineffective. The DNP nurse
also participates in the continual gathering and evaluating of current research on the
management of IC/PBS and translates new findings into clinical protocols to improve
patient outcomes. Consistent use of the management techniques for IC/PBS supported
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by high quality evidence and continuing education on evidence based practice
guidelines for healthcare providers will lead to better patient outcomes.
Implications for Research
Scholarship and research are the hallmarks of a doctoral level education. DNP
nurses participate in scholarship through the translation and application of knowledge
and the integration and synthesizing of information into practice (AACN, 2006). Need
exists for the advancement of the body of knowledge regarding the management of
IC/PBS in women. Current well-designed studies on the effectiveness of nonpharmacological management strategies for IC/PBS are not available. Further study of
pharmacological interventions is also needed to better determine the most effective
way to manage IC/PBS in women. In addition to participation in gathering new scientific
knowledge on the management of IC/PBS, DNP nurses have the opportunity to translate
this research into best-practice protocols for diagnosing and managing IC/PBS in primary
care and specialty practice. One of the roles of the DNP nurse as a researcher is to
collaborate with PhD prepared nurses in discovery research to provide new treatment
options for patients. In the practice setting, the DNP nurse enhances research by
collecting new data. The DNP nurse partners with other doctoral level practitioners to
synthesize and interpret this data and make new treatment recommendations. The
DNP prepared nurse adds his/her experience from the clinical setting to tailor
recommendations for the practice setting for implementation and improved patient
outcomes.
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Implications for Leadership
The Essentials of Doctoral Education for Advanced Nursing Practice published by
the AACN states that, “doctoral education in nursing is designed to prepare nurses for
the highest level of leadership in practice and scientific inquiry.” (2006, p.7). DNP
graduates are prepared to develop and evaluate care delivery approaches that meet
current and future needs of patient populations based on scientific findings and
enhance the quality of health care for populations with whom they work (AACN, 2006).
The healthcare provider caring for adult women should be familiar with the best
practice for recognizing and managing IC/PBS. The DNP nurse demonstrates leadership
in the field by providing education on best practice management of IC/PBS to other
healthcare providers to improve quality of care and outcomes for women with IC/PBS.
As evidenced by the study by Clemens et al. (2010), and personal experience,
there is a lack of knowledge and understanding of IC/PBS. Primary care providers are
not aware of which patients to screen for IC/PBS or how to treat patients that providers
suspect have IC/PBS.
Strategies for this project focused on improving policy in two primary care rural
settings with a focus on educating providers about IC/PBS diagnosis. Particular
attention was given to patients who had been frequently treated for UTIs and either had
not had a urine culture done or were treated with an antibiotic despite a negative
culture. In these rural health care settings, primary care providers had to begin
treatment for IC/PBS and help the patient manage symptoms. Providers were educated
on first line treatments of stress reduction and initiation of PPS to improve patients’
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symptoms. Providers were receptive to education and implementation of
recommendations into practice. After receiving continuing education, providers
conducted urine cultures on every woman frequently presenting with symptoms of UTI
ruling out the presence of bacteriuria and promoting a possible diagnosis of IC/PBS.
Implications for Policy development
According to the ANCC Essentials for Doctorate Education, DNP graduates must
be skilled in working within organizational and policy arenas in addition to the actual
provision of patient care (AACN, 2006). DNP nurses are proficient in quality
improvement strategies and in creating and sustaining changes in the organization and
policy (AACN, 2006). Leadership from DNP nurses in policy development is essential to
the nursing profession and the patients they serve (AACN, 2006). The purpose of
institutional and practice policies are to ensure best practice, safe practice, optimal
patient outcomes and cost-effective treatment of patients. DNP nurses contribute to
policy development by serving on development councils and contributing to decisions
made through direct involvement or education of others involved in policy development
(AACN, 2006). Policy development in the author’s primary care practice, related to the
management of IC/PBS, is currently in progress. This policy will provide guidance on
treatment of IC/PBS, improving patient outcomes.
Summary
IC/PBS is a chronic condition affecting millions of women in the United States
that is often unrecognized and undiagnosed (Burkman, 2004; Forrest & Moldwin, 2008).
DNP advanced practice nurses are in the unique position to manage IC/PBS in women,
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educate patients and other healthcare providers about the disease, contribute to new
research, and contribute to the development and implementation of best practice
guidelines and policies to improve patient outcomes.
DNP advanced practice providers use the most current literature to improve
their practice and patient outcomes. Literature on the management of IC/PBS
supported the use of oral PPS for management of IC/PBS (Dimitrakov et al., 2007; Nickel
et al., 2005; Nickel et al., 2008; Sand et al., 2008). The literature did not support the use
of amitrypline, cemetidine, or hydroxyzine for management of IC/PBS (Dimitrakov et al.,
2007; Hill et al., 2008; Unwin, 2011). Behavior modifications and coping strategies
provided some symptom improvement (Chaiken et al., 1993; Rothrock et al., 2003).
Best practice management of IC/PBS should focus on setting realistic goals with a
patient for an acceptable quality of life, incorporation of behavior medications,
appropriate coping strategies and oral PPS. Further research on the management of
IC/PBS is needed, particularly of non-pharmacological therapy and oral medications as
alternatives to PPS. New research and the development of evidence based protocols for
the management of IC/PBS provides many opportunities for DNP advance practice
nurses to participate in new research and translation of research into practice.
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APPENDIX A
Table A.1: Evidence Tables
Brief
Reference
(Anderson &
Perry, 2006)

Type of study/
Grade
Review of literature/
3

Methods
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Authors searched
medical literature
published in any
language since 1980 on
pentosan polysulfate.
Search engines used
were MEDLINE,
EMBASE and AdisBase.
Results were
supplemented with
references from the
bibliography of
published articles. The
Search terms used were
‘pentosan polysulfate’
or ‘pentosan
polysulfate’ and
‘interstitial cystitis’.
Studies were selected
for inclusion based on
methods of selection

Threats to validity/
reliability
The strength of the
evidence found was not
discussed and
recommendations were
not graded. The authors
state that When
available large, wellcontrolled trials were
preferred, however, they
do not discuss how many
of these studies were
large well-controlled
trials.

Findings

Conclusions

PPS is a semisynthetic, sulfated
polysaccharide
chemically similar to
heparin. The exact
pharmacokinetics are
not well understood,
it is thought that it
repairs the GAG layer
on the bladder
epithelium reducing
permeability to toxins
from the urine. It
may also reduce
histamine secretion
thereby reducing
inflammation.
Bioavailability of PPS
is very low. Welldesigned trials found
that compared to

PPS has shown
beneficial effect in a
large proportion of IC
patients. It improves
the patients’ overall
condition and provides
pain relief. It is
generally well tolerated
and side effects are
usually mild. Current
literature supports the
use of PPS as an
important option in the
treatment of IC.

Brief
Reference

Type of study/
Grade

Methods
used in the trials. When
available large wellcontrolled trials were
preferred.

Threats to validity/
reliability

Findings
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placebo PPS was
more effective at
treating moderate to
severe IC. In patients
with less severe IC
PPS was not
significantly different
from hydroxyzine and
less effective than
cyclosporine. Noncomparative studies
of long-term
treatment show that
PPS significantly
reduces pain over
time. Use of PPS and
heparin was shown to
be more effective
than either alone,
however use of PPS
and hydroxyzine
together is not
significantly different
than use of either
alone.

Conclusions

(Chaiken et al.,
1993)

Case study/3
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42 women previously
diagnosed and treated
for IC were selected to
participate in
behavioral therapy for
refractory symptoms of
urgency, frequency and
suprapubic pain related
to IC. These women
participated in an 8 to
12 week course of 1 45minute behavioral
therapy session per
week. Women were
asked to keep a voiding
journal, inter-voiding
interval; number of
micturitions per day
and a global assessment
scale were used to
measure effectiveness
of therapy. An

experienced therapist
with training in
psychology and lower
urinary tract
physiology performed
therapy. Baseline
values for total
daytime void
volumes, maximum

Data rely on the
accuracy of participants
to a keep a voiding
journal. 16 participants
were excluded from the
results because of a
failure to keep the
voiding journal.
Behavioral therapy
requires highly
motivated patients and
skilled therapist many IC
patients may not comply
with the requirements of
this therapy. All women
participating in this study
had tried other
treatments for IC such as
medications, intravesicial
instillations, and
mechanical
interventions, none of
which provided lasting
relief, these women may
be more motivated to
complete behavioral
therapy than the average
IC patient.

21 participants
reported that their
global assessment
scale symptoms ere
markedly improved,
and 16 stated that
they were improved.
Those who had
markedly improved
symptoms had an
average increase
interval between
voids of 123 minutes
and an average of
voiding 6 times per
day. The functional

bladder capacity
increased in 38 of
42 patients
(p<0.01), intervoiding interval in
creased in all
patients by an
average of 93
minutes (p<0.01),
the maximum
interval increased in
38 of 42 patients
(p<0.01) and 41
patients

Behavioral therapy
does improve global
symptoms assessment
scores and increases
intra voiding intervals,
and decreases number
of voids per day. This
therapy is effective for
the highly motivated
patient who has access
to a skilled therapist.
However only a small
percentage of patients
with IC agree to
undergo this
treatment, as it is labor
intensive.
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voided volume, mean
voided volume,
maximum and mean
inter-voiding intervals
and total number of
micturitions were
recorded. Post
treatment values in
the same categories
were determined and
patients were asked
to rate their global
results of therapy as
markedly improved,
improved,
unimproved or worse.
This data was then
analyzed with the
student’s t test.
(Dell, 2007)

Expert opinion/ 4

Dell presents a review
of literature related to
the differentiation
between UTIs and
IC/PBS, and the
diagnosis and
management of IC/PBS

experienced a
decrease in the
number of
micturitions a day
by an average of 9
(p<0.01).

Dell does not rate the
evidence that he has
reviewed leaving it hard
for the reader to draw
their own conclusions as
to how reliable the
recommendations are.

IC/PBS is a challenge
to diagnose as
patients have a range
of symptoms that
overlap with other
disorders, such as
UTI. May patient s
are treated
empirically with
antibiotics even
though their urine

A urine culture is all
that is needed to
differentiate a UTI from
possible IC/PBS. IC/PBS
is more common than
once thought, patient
care can be improved
by completing a urine
culture on patients
presenting with irritate
voiding symptoms.

cultures are negative
and they are later
diagnosed with
IC/PBS

88

(Dell & Butrick,
2006)

Literature review and
expert opinion/ 4

The method of
literature review was
not discussed in this
publication.

The method of literature
review was not
discussed, the quality of
articles found and used
in the article were not
graded making it difficult
to judge the quality of
these recommendations.

The exact cause of IC
is unknown making
finding a targeted
cure impossible.
Recent experience
demonstrates that
symptoms can be
managed. A
scientifically rational
approach is a
multimodal
treatment strategy
directed toward
treatment of the 3
components
considered key to the
pathogenesis of IC.
The dysfunctional

Management should
focus on a multimodal
approach combining
oral and intravesical
pharmacological
treatment with diet
and lifestyle
modification and other
non-pharmacological
potions, including
stress reduction,
exercise, bladder
training, biofeedback
physical therapy.
Non-pharmacologic
therapies that can be
combined with
medications to
enhance outcomes
include diet
modification to avoid
foods high in potassium
and acid. In patients
with pelvic pain
associated with
concomitant pelvic
floor muscle
tenderness and spasm
restoration of normal
tone and function
though physical
therapy and home

bladder epithelium,
associated allergies,
and neural
upregulation. The
benefits of
pharmacologic
interventions can be
enhanced with
dietary changes,
physical therapy and
bladder retraining.
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exercise to realign the
sacrum and ileum by
internal direct manual
therapy of the pelvic
floor muscles is helpful.
Bladder training and
biofeedback are also
helpful. Pharmacologic
treatment should start
with the only FDA
approved medication
for IC pentosan poly
sulfate sodium (PPS).
PPS appears to
replenish the defective
mucous layer and
restore bladder
integrity it is currently
the most effective
treatment for IC. Other
pharmacologic
treatments that may be
used in conjunction
with PPS include
antihistamines, TCAs,
analgesics,
anticholinergics,
estrogen creams and
cycle suppression with
continuous OCPs, and
skeletal muscle
relaxants.

(Dimitrakov et
al., 2007)

Systematic review of
RCT/ 1++

90

RCT for pharmacologic
treatment of patients
with IC diagnosed based
on the NIDDK definition
of IC or operational
criteria were included in
the review. Nine
databases were
searched including
Pubmed, CINAHL, Web
of Science the Cochrane
Collaboration Reviews
and others. Terms
included Interstitial
cystitis, and painful
bladder syndrome.
Other key words were
those that described
the publication as
randomized, double
blind, random
allocation, placebo,
clinical trial and
comparative study. All
studies were limited to
those published in
English and those that
studied adults. Only
trials for PPS had
sufficient numbers to
allow a pooled analysis.
A total of 1470 adult

The patient sample was
heterogeneous, possibly
making generalization to
the general population
difficult. There was
considerable variability
in the definition of
symptoms and in
outcome assessments
among the RCTs
reviewed.

A pooled estimate of
the effect of PPS
therapy suggests
benefit from this
therapy with a
relative risk of 1.78
for patient-reported
improvement in
symptoms. Current
evidence also
suggests that
dimethyl sulfoxide
and amitriptyline are
effective therapy for
IC. Hydroxyzine,
intravesical bacilli
Calmette-Guerin and
resiniferatozin
therapies failed to
show significant
efficacy.

PPS therapy has shown
modest improvement
in symptoms of IC.
There is insufficient
evidence to
recommend other
pharmacological
therapies.

(Forrest & Dell,
2007)

Clinical article/ 4

patients from 21 RCT
were used.
Methods of literature
review are not
discussed

This article is based on a
review of literature and
expert opinion. The
strength of the literature
and the qualification of
the authors are not
presented.
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PCPs, urologists, and
OB/GYNs have the
opportunity to detect
and provide effective
management of IC in
its early stages.
Treatment should
include counseling on
lifestyle modification
to avoid triggers such
as high potassium
foods, and allergens.
First line therapy is a
combination of oral
medications including
PPS. Preliminary data
shows that
intravesical treatment
may help relieve
symptoms in the
period before PPS
reaches its full effect.
Patients should be
reevaluated between
1 and 3 months of
starting treatment.
Biofeedback and
neurostimulation
have also been shown
to be effective.

Management of IC is
multimodal using a
multi drug oral regimen
including PPS. And
other therapies
patients may require
including intravesical
instillations,
biofeedback, and
neurostimulation.

(Forrest &
Mishell, 2009)

Expert opinion/4

Recent literature was
reviewed by a panel of
leaders in urology,
gynecology,
urogynecology and
general women’s health
to reach a consensus
and formulate
algorithms for
diagnosing and treating
IC/PBS

The paper is based on
the consensus of experts
and the “recent
literature reviewed” is
not described or ranked.
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IC is the cause of a
large portion of
chronic pelvic pain
(CPP), suggesting that
the diagnosis of IC
should be a diagnosis
of inclusion, and
should be considered
at the same time as
other common
diagnoses rather than
only when other
causes have been
ruled out. Primary
goals of treatment
are relief of pain and
improvement of
quality of life. The
factor that correlated
most strongly with
favorable therapeutic
response was
duration of symptoms
prior to treatment;
early treatment
provides better
outcomes.

Many women with CPP
are symptomatic for
longer than necessary
because of missed or
late diagnosis. IC
should be considered
as a source of CPP early
in the diagnostic
process to prevent
unnecessary
gynecologic surgery.
Clear diagnostic criteria
for IC must be
identified; the hope of
the expert panel is that
the algorithms
provided here serve
that purpose.
PPS has undergone
prospective
randomized trials and
was shown to have
significant symptom
improvement over
placebo. 90% of
patients report that
certain foods
exacerbated
symptoms. Multimodal
treatment should
include a behavioral
component to optimize

Review of literature
and expert opinion/4

Experts in management
of IC/PBS discussed
tools available to
diagnose and treat IC
and the advantages and
disadvantages of each
approach. Researchers
also reviewed literature
for relevant articles on
the background,
diagnosis, and
treatment of IC with a
focus on the
importance of early
intervention.

The authors do not
discuss the qualifications
of the experts who
contributed to this
review. They also do not
discuss the quality of the
literature available and
reviewed.

Diagnostic options for
IC include history and
physical exam, lab
evaluations, symptom
screening tools,
cystoscopy with
hydrodistention,
bladder biopsy, PST,
ABC, urodynamics
and urinary markers.
Treatment options
include oral and
intravesical
medications, dietary
modifications and
physical therapy.
Patient follow –up is
an important
opportunity for
education.

(Hanno et al.,
2011)

Guideline

A committee of
urologist, nurses and
other clinicians with
specific expertise on
IC/PBS developed the
AUA guideline. The
committee conducted a
systematic review of

Only the database of
MEDLINE was searched,
possibly limiting the
search and excluding
some valuable studies.
Because of a lack of
evidence expert opinion
is used to make some

First through sixth
line treatments were
recommended. A
treatment algorithm
was provided to
summarize these
findings. First line
treatment is
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(Forrest &
Moldwin,
2008)

Guideline
AGREE Score:
Scope &
purpose=78%
Stakeholder

patient outcomes.
Most treatment
options take time to
take full effect
encouragement to
adhere to treatment
plan is important. Nonpharmacological
treatments such as
dietary modification,
stress and anxiety
reduction, exercise,
physical therapy,
counseling, bladder
training and pelvic floor
rehabilitation can be
beneficial and enhance
pharmacologic
management.
Regardless of
treatment approach
early identification of IC
improves patient
outcomes.
IC is best managed
through a logical
algorithm such as the
one presented in this
paper. Diagnosis and
treatment options can
be expected to change
as there is currently

involvement=67%
Rigor= 71%
Clarity=92%
Applicability=11%
Editorial
independence=67%

94

MEDLINE of
publications in English
published between
1/1/1983 and
7/22/2009. Metaanalysis of Randomized
controlled trials and
systematic review were
used to analyze the
evidence. Grades of A,
B or C were given to
bodies of evidence to
indicate the strength of
the evidence available
for particular
recommendations.
Grade A were wellconducted RCTs or very
strong observational
studies; grade B
consisted of RCTs wit
some weakness of
procedure or
generalizability or
strong observational
studies; Observational
studies that are
inconsistent, have small
sample sizes or have
other problems that
confound interpretation
of data were graded

recommendations rather
than systematic review
of literature. By limiting
the included studies to
those conducted in the
US it is possible that
valid treatments that
should be considered
have been excluded.
The cost of these
recommendations is not
address the authors also
do not provide
monitoring criteria for
audit because this is
inherently difficult with
this disease process.
They also do not provide
a process for
revision/update but
simply state that the
guideline will be
updated, as more
research is available. The
panel chosen to write
this guideline is made up
of experts in Urology and
IC/PBS; there is a full
disclosure of any
conflicts of interest.

considered to be
general relaxation
and stress
management, pain
management,
education and
behavior
modification. Pain
management should
be addressed at all
stages of treatment.

little evidence on the
subject and as more
evidence is provided
recommendations will
change. No single
treatment is found
effective for the
majority of IC patients.
First line treatment is
education, self-care
practices and
behavioral
modifications such as
diet changes, stress
management and
pelvic floor muscle
relaxation and bladder
training. PPS and other
prescription
medications are
considered second line
treatment because
administration is
associated with minor
adverse events and
efficacy for individuals
is unpredictable.
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level C. Insufficient
evidence was found on
the diagnosis o f IC/PBS
recommendations were
made based on clinical
principles and expert
opinions. The AUA
defines clinical principle
as a statement about a
component of clinical
care that is widely
agreed upon by
urologists or other
clinicians for which
there may or may not
be evidence in the
medical literature.
Expert opinion is
defined as a statement
that is achieved by
consensus of the
committee based on
members clinical
training, experience,
knowledge and
judgment for which
there is no evidence.
The Cochrane Risk of
Bias tool was used to
assess individual studies
that were RCTs. Studies
addressing treatments

(Hill et al.,
2008)

Cross sectional
survey/3
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not available in the US
using herbal
supplements and
information collapsed
across multiple
interventions were
excluded.
750 patient diagnosed
with IC completed a
computerized Internet
survey that was linked
on the Interstitial
Cystitis network,
national Women’s
Health Network and
Our Bodies Ourselves
websites. The survey
questioned patients
about demographics,
symptoms, co
morbidities, treatments
and perceived
treatment outcomes.
Statistical analysis was
conducted using SPSS
statistical software,
descriptive statistics
were calculated and
person chi-squared
tests were used to
compare the
percentage of patients

Survey studies are
Hydrodistention,
subject to risks involving intravesicular
inaccurate self-reporting. therapy, and urethral
dilation were the
most common
invasive treatments
used. Of these
procedures 27-49.8%
of patients felt no
effect, 24.4-45.3%
were improved, and
25.9-30.7% felt
symptoms worsened.
2.7% (395) of the 750
individuals surveyed
had taken PPS 53.4%
found that the
medication improved
IC symptoms, 3.8%
felt that it made
symptoms worse,
29.9% felt that it did
not have any effect
and 12.9% of patients
felt PPS side effects

The majority of patient
reported that
medications improved
their condition.
Medical therapy is
perceived to be better
than invasive therapy
for IC. Medications
that were perceived to
improve IC symptoms
include PPS, calcium
glycerophosphate
(Prelief OTC),
Amitriptylne,
phenazopyridine, and
Codine. Vistaril,
tolterodine,
oxybutynin,
oxybutyninXL, and
diphenhydramine
appear to have no
significant effect on IC
symptoms.

who fell into each of the
three groups based on
their perceptions of
each treatment:
improved, no effect or
made worse.
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(Nickel et al.,
2005)

RCT, double-blind/
1+

Three dosages of
pentosan polysulfate
sodium (PPS) were
evaluated in a
randomized, double
blind, double-dummy,
parallel-group
multicenter 32-week
study. 380 adults with
a diagnosis of IC were

The completion rate of
the study was 60%, not
unexpected by the
authors given the length
of the study. There was
not a comparable
placebo group. Most of
the patients who
participated in this study
had moderate to sever

were intolerable
(P<0.001). Other
medications that
significantly improved
patients’ perception
of IC symptoms
include
phenazopyridine,
calcium
glycerophosphate
(Prelief),
amitriptyline, and
codeine. Vistaril,
tolterodine,
oxybutynin,
oxybutyninXL, and
diphenhydramine
were reported by the
majority of patients
to have no effect on
IC symptoms
(p<0.001).
No statistically
significant difference
in response among
the three dosages of
PPS was found. There
was significant
improvement in the
average ICSI scores
(p<0.001) over the
32-week period in all

Dosages of 300mg,
600mg, and 900mg of
PPS all show clinically
significant results in
reduction of symptoms
of IC, however the
difference between the
dosage groups is not
significant. Duration of
therapy appears to be
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(Nickel et al.,
2008)

Secondary analysis of
RCT/2-

randomly assigned to
dosage groups of 300
mg, 600 mg or 900 mg
of PPS. Patient
symptoms at base line
at points during the
study and at the end of
the 32 weeks were
evaluated using the
O’Leary-Sant IC
Symptom Index (ICSI)
and the Patient’s
Overall Rating Symptom
Index (PORIS). Results
were analyzed using a
two sample t test and
chi square analyses with
a significance level of
alpha=0.05.

symptoms of IC and a
better understanding of
the treatment effect of
PPS may be gained by
studying patients in early
stages of IC.

dosage groups.
Earliest improvement
in ICSI scores was
seen in 4 weeks.
Patients with severe
baseline symptoms
responded better to
600mg dose of PPS
(p=0.028). 17-23% of
participants saw
improvement in ICSI
scores in 4 weeks by
the end of the study
(32 weeks) 59 to 67%
found improvement
of symptoms.

Retrospective
secondary analysis of a
previously published
32-week multi center
randomized, double
blind. A subset of 128
women who received
PPS 300mg/day were
analyzed in this study.

The original RCT did not
have a placebo group.
The time from diagnosis
to initiation of PPS was
used to evaluate time
until initiation of
treatment and is not
representative of time
since IC symptoms

The ICSI score for the
early treatment group
had an average
improvement score of
3.97 points compared
to an improvement of
2.15 points in the late
treatment group
(p=0.0472). The ICPI

more important that
the dosage of PPS.
Over half of study
participants found
relief by the end of the
32-week period even if
they did not have
significant symptom
relief at the four-week
measurement. Even
though this study lacks
a control group and
participants were IC
patients with moderate
to sever symptoms the
methodology of this
trial provides strong
scientific evidence to
support therapy
including PPS as
beneficial for the relief
of symptoms in women
with IC.
Early recognition of IC
and prompt initiation
of treatment may lead
to more improvement
in IC symptoms and
response to therapy.
Individuals treated with
PPS within 6 months of
diagnosis showed
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(Onwude,
2009)

Literature review/ 4

Participants were
further sub-categorized
as receiving early
treatment with PPS
(initiation with in 6
months of diagnosis
with IC) and late
treatment (initiation of
treatment 24 months or
more after diagnosis of
IC). Outcome measure
included the ICSI and
the ICPI. Scores from
the ICSI and ICPI were
compared using an
analysis of covariance
ANCOVA model that
included the category
for time since IC
diagnosis as a factor
and baseline score as a
covariate. All statistical
tests were performed at
a 5% significance level.
Externally peer
reviewed clinical article
published in the British
Medical journal with
the goal of highlighting
areas of practice where
management lacks
supporting evidence.

began, especially since
many patients with IC
suffer from symptoms
for moths or years
before diagnosis. Both
the early and late
treatment groups had
moderate to sever IC
symptoms at baseline
making it difficult to
generalize to patients
who experience mild IC
symptoms. The majority
of patients had also
received at least on IC
medication before
enrollment in the study,
which may have created
an unknown bias.

showed similar
results with an
average improvement
of 3.94 points from
baseline in the early
treatment group and
1.77 points in the late
treatment group
(p=0.0117). This
exploratory analysis
suggests that subjects
with IC benefit from
earlier initiation of
PPS therapy. Those
who received PPS
within 6 months of
diagnosis showed
significantly greater
improvement in both
ICSI and ICPI scores.

significant
improvement in
symptoms scores and
symptom bother scores
compared to those who
did not receive PPS
until 24 moths or more
after diagnosis. Earlier
initiation of therapy for
IC may provide more
benefit to patients
diagnosed with IC.
Early diagnosis and
treatment may be the
key to better
management of IC and
maybe prevention and
progression of the
disease.

The method of literature
review is not discussed.
The quality of literature
available is not
discussed, the author
does note that the
quantity of quality
evidence is lacking.

IC currently has no
standardized
treatment and
current randomized
drug studies offer
conflicting results.

A systematic review of
oral treatments for IC is
needed. Patients and
clinicians should
understand the
limitations of evidence
for current treatments
and set realistic

Non-systematic
review of literature
and expert opinion/4

Discussion of IC through
review of literature and
author’s experience as
an expert in treating IC
for 20 years.

The rigor to which the
literature was reviewed
was not discussed. The
author relies on 20 years
of experience and the
treatment of more than
5,000 IC patients to give
himself credibility as an
expert.

IC is a relatively
common disorder
that cam be
recognized in its early
stages and treated
with a high measure
of success.

(Parsons,
2006)

Expert opinion/ 4

The article summarizes
the latest advances in
medical treatment of IC
based on opinions of
experts in the field and
their experiences in
practice.

This article is based on
clinicians’’ experience in
treating women with IC
rather than rigorously
designed clinical trials.

Most individuals are
affected by a mild to
moderate form of IC
that responds to
treatment. A
heparinoid-based
multi modal medical
regimen can
effectively control
symptoms and
address disease
pathology.
Intravesical solutions
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(Parsons,
2002)

treatment goals.
Treatment should be
based on restoring
epithelial function with
heparinoids such as
intravesicular heparin
or oral PPS; modulating
neural activity, with
TCAs; and controlling
allergies. Oral PPS had
been effective in
treating IC, duration of
treatment is more
important than dose.
Yong patients 18-30
generally have good
symptom improvement
with oral PPS over 2-4
months.
PPS has been shown to
successfully treat IC in
RCT however these
studies do not explore
the added benefit of
longer duration of
treatment and use with
ancillary treatments.
Duration of PPS
treatment is at least as
important as dose.
Heparinoid therapies
do not treat the

are new and
promising adjunctive
therapies that can
offer immediate
symptom relive in
flares.

(Quillin &
Review literature and
Erickson, 2012) expert opinion/ 4
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The authors review the
AUA guideline on the
diagnosis and
treatment of interstitial
cystitis/bladder pain
syndrome and
comments on the
practical
implementation of the
guideline and the most
recent research.

Strength of other
literature reviewed is not
discussed. Very little
guidance is added to
treatment approach
other than what is
offered by the AUA
guideline itself.

Treatment should
progress form
conservative to more
invasive therapies
with the goal of
attaining acceptable
quality of life.
Assessment of
symptom level and
reassessment post
intervention
evaluates efficacy.
Concurrent
treatments may be
used if in the
patient’s best
interest.
Pain management
should be continually

symptoms of IC they
correct the dysfunction
of the epithelial lining
of the bladder.
Successful
management of IC is
achieved through
multimodal therapy
with heparinoid
therapy.
Diagnosis of IC/PBS is
now made based on
history, physical exam,
frequency-volume
chart, UA, and culture
not on cystoscopy or
urodynamics.
Treatment focuses on
education, diet, and
stress management.
Oral medications and
bladder instillations
should be considered
second line therapy
and side effects and
polypharmacy should
be avoided.

assessed.
Self care practices
and behavioral
modification should
be discussed and
implemented first.
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(Rosamilia,
2005)

Clinical article/ 4

The methods of
literature review were
not discussed in this
article. The author does
make treatment
recommendations and
gives each
recommendation a
grade, however she
does not define her
grading system or
discuss her evidence.

The lack of a methods
section makes it difficult
to determine the
strength of evidence
reviewed for these
clinical
recommendations.

Amitriptyline,
cimetidine,
hydroxyzine, or PPS
may be administered
as second-line oral
medications.
This article reviews
the definition,
diagnosis and etiology
of IC for the clinician
and provides graded
recommendations for
management
including physical
therapy, behavior
modification, diet
manipulation, oral
therapy, and
intravesical therapy.

Behavior modification,
physical therapy and
dietary manipulation
are all offered as
treatments for IC,
however the author
does not provide a
grade for these
recommendations.
Treatment with PPS
and Amitriptyline
received a grade B
recommendation, and
evidence for treatment
with Hydroxysine,
Cimetidine,
immunoregulators,
antibiotics,

(Rosenberg,
Newman, et
al., 2007)

Clinical article/ 4

Methods of collection
of literature are not
discussed.
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Unable to determine the Over time IC/PBS can
strength of the data used become debilitating,
to complete this article.
and result in
limitations to
patient’s personal
and professional life.
Patients with IC/PBS
are 5 times more
likely to be treated
for an emotional
disorder than those
without IC. The
cornerstone of
treatment is
behavioral therapy.
This included
educating patients
about symptoms,
behavioral
modification to
decrease urgency and
frequency, physical
therapy to release
trigger points, stress
reduction, and diet
modification.
Multimodal
pharmacotherapy

cyclosporine and
analgesics was limited
leading to a grad D
recommendation.
IC has a higher
prevalence that once
realized. IC/PBS has a
significant impact on
the quality of life. Early
identification and
initiation of therapy
leads to better
outcomes. Multimodal
therapy including
behavioral therapy and
multiple drugs are the
standard treatments.

(Rothrock et
al., 2003)

Case reports/3
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64 women with IC were
recruited from the
department of urology
and the participating
institution. All were
diagnosed with IC based
on the NIDDK
guidelines. Participants
completed
questionnaires
assessing depression,
quality of life, coping,
and symptom severity
and a standardized
semi-structured
depression interview.
Descriptive statistical
analysis was performed
for demographic
variables. For each
dependent variable
regression models were
constructed to test the
relationships among
coping strategies,
quality of life and
depression. Age and
symptom severity were
covariates in these

89.1% of the sample was
white and the majority
of participants were high
school graduates or
higher level of
education, this sample
may not be
representative of the
general population of
women with IC. The use
of the NIDDK guidelines
for diagnosis of IC is
considered to be too
restrictive for clinical
practice. Women in this
study may differ in
symptom severity from
the average women with
IC because they meet
these strict criteria for
diagnosis.

consists of PPS,
hydroxyzine, and
Amitriptyline.
Age and symptom
severity were not
associated with
depressive symptoms
or mental health.
However, greater
catastrophizing was
related to more sever
symptoms on all
measures of mental
health (p<0.05).
Venting was
associated with more
depressive symptoms
(p<0.01) while
seeking instrumental
support was
associated with a
decrease in
depressive symptoms
(p<0.01). Yonger age
(p<0.05) and
increased symptoms
severity (p<0.001)
were significantly
associated with
increased pain.

Maladaptive coping
strategies are
associated with higher
levels of depressive
symptoms and
decreased quality of
life in patients with IC.
Psychosocial
interventions aimed at
increasing adaptive
coping may improve
outcomes for women
with IC.

(Sairanen et
al., 2005)

Randomized Control
trial/1+
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models. All analyses
controlled for age.
64 patients meeting the
NIDDK criteria for
diagnosis with IC were
enrolled in a
randomized prospective
study. Participates
were randomly
assigned to treatment
groups with 1.5 mg/kg
CyA BID or 100mg of
PPS TID for a 6 month
period. Daily
micturition frequency
and ICSI and ICPI were
used to evaluate
treatment success.
Baseline factors were
compared with t test
and the Mann-Whitney
rank sum test, and
differences between
treatment outcomes
were calculated with
the Mann-Whitney rank
sum test.

The NIDDK criteria for IC
is very restrictive and
this study may not be
representative of how all
IC patients would react
to treatment,
particularly those with
early onset, mild
symptoms. Sample size
was relatively small 29
patients completing the
study in each treatment
group.

Reduction of
micturition frequency
in 24 hours by 50%
was not seen in any
of the patients in the
PPS treatment group,
and in 11 (34%) of
patients in the CyA
group (p<0.001). CyA
was also significantly
more effective than
PPS in all other
parameters measured
(p<0.001).

Researchers state that
PPS has not been found
effective for IC patients
meeting the NIDDK
criteria for diagnosis,
however, it is possible
that PPS works better
for patients with a
milder form of IC and in
earlier stages. CyA
treatment is
recommended for
patients with severe IC
meeting the NIDDK
criteria, particularly
those who have failed
other treatments.
Careful follow up
including regular
monitoring of BP and
serum creatinine is
mandatory.

(Sairanen et
al., 2009)

Second analysis of
Randomized control
trial/1-
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2 consecutive studies of
treatment for IC/PBS
were conducted. One
compared 75 patients
with IC were
randomized into either
the DSMO intravesicular
treatment group or the
BCG intravesicular
treatment group. The
second study 64
patients were
randomized into either
oral cyclosporine A
treatment group or PPS
treatment group. All
patients included had to
meet NIDDK criteria for
diagnosis with IC. QOL
was evaluated with a
30-item questionnaire.
Questionnaire results
were evaluated for each
treatment group using
the Wilcoxon rank sum
test. A one-way ANOVA
was used to evaluate
the similarity of
baseline characteristics
of treatment arms.

Self reported
questionnaires are
always subject to bias.
Also treatment groups
were relatively small.
The use of NIDDK criteria
for diagnosis with IC may
have limited inclusion of
patients with IC and limit
the study’s ability to be
generalized to the larger
population of women
with IC.

All patients who
showed a response to
their specific
treatment had an
improved score on
QOL questionnaires.
CyA treatment group
had more
improvement in
emotional well-being,
social functioning,
activity limitation and
physical capacity than
PPS (p<0.001). More
patients responded to
DMSO than BCG
(p<0.01), but results
on QOL
questionnaires were
equal after either
treatment.

The health related
quality of life
questionnaire could be
used to evaluate QOL in
patients with IC. It has
never been used to
evaluate IC/PBS
patients prior to this
study. Treatment of IC
has a significant effect
on QOL and QOL can be
used to evaluate
success of treatment.
A QOL questionnaire
specific to IC needs to
be developed and
validated. CyA therapy
has a greater impact on
the majority of the
categories of QOL
measurements than
PPS.

(Sand et al.,
2008)

Secondary analysis of
RCT/2-
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Retrospective
secondary analysis of a
previously published
32-week multi center
randomized, double
blind, parallel-group
clinical trial of 380
women. A subset of
128 women who
received PPS
300mg/day were
analyzed for treatment
response using they
O’Leary-Sant ICSI and a
treatment satisfaction
questionnaire. Women
were labeled as
responding to PPS
treatment if they had a
greater than or equal to
30% reeducation in the
ICSI score from
baseline.

The original RCT did not
have a placebo group
and the treatment
satisfaction
questionnaire is not a
validated instrument.
However the O’LearySant ICSI is validated for
the evaluation of IC
symptoms. 91% of
subjects were women
with moderate or sever
symptoms at baseline,
making it difficult to
generalize this data to a
population of IC patients
with mild symptoms.
The sub-sample from the
original RCT analyzed in
this study was relatively
small (n=128).

49 women (42%) with
a greater than 30%
reduction in ICSI score
from baseline were
identified as
responders to PPS
treatment. These
women were more
likely to be pleased
with PPS for
treatment of IC
symptoms
(p<0.00101), to have
benefitted from PPS
(p<0.0001) and to
recommend PPS to
other patients with
similar symptoms
(p=0.0466). 79% of
responders found
that PPS provided
better relief than
other treatments
tried (p=0.0038).
Among all subjects
more than 70%
reported a benefit
from PPS at the end
of the treatment
period, even if they
were not identified as

70% of subjects
reported a benefit from
PPS including more
than a third of those
classified as nonresponders. Many
participants also
reported greater
symptom relief with
PPS compared to
previous treatments for
IC symptoms. A
significantly higher rate
of symptom reduction
and satisfaction was
reported with PPS
therapy. PPS therapy
has a significant
positive correlation
between ICSI score and
the patient response
score on the individual
questions in the patient
treatment
questionnaire.
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(Schmid et al.,
2011)

Cohort study/ 2-

69 female patients
diagnosed with IC based
on the NIDDK standards
and histories of
unsuccessful treatment
were included. Patients
were evaluated prior to
treatment and two
weeks after each step in
the treatment
algorithm for sexual
functioning, and quality
of life. If a patient was
satisfied with current
treatment it was

Using the NIDDK criteria
may limit the number
and type of IC patients
that were included in the
study. In addition using
patients who had
histories of failures with
other treatments might
suggest that these
patients have more
severe symptoms that
the general population
of IC patients.

responders. This
suggests that even
non-responders
would have ICSI
scores showing a
trend toward
improvement. A
substantial
proportion of nonresponders also
reported that they
relief that they found
with PPS was greater
than the relief that
they had found with
previous treatments
for IC.
Researchers found
that a stepwise
approach to
management if
symptoms with
tetracycline, oral
steroids, and
antihistamines
significantly improved
sexual function and
quality of life in
women with IC/PBS.
VAS scores for pain
improved significantly
after receiving

This study shows that a
stepwise approach to
therapy with
tetracycline, bladder
instillation with
heparin/local
anesthetic, oral
steroids,
antihistamines, and
DMSO instillation
significantly improved
sexual function and
quality of life in IC
patients. Improvement
in all domains of sexual
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considered a success
and the patient did not
progress to the next
step of the algorithm, if
the patient continued
to have symptoms the
next step was
implemented. The
King’s Health
Questionnaire was used
to assess quality of life
and the visual analogue
scale (VAS) 0-10 was
used o assess symptom
bother. A two-tailed t
test was performed to
compare scores before
and after treatment.
(Shorter, 2006)

Expert opinion with
case study/ 4

This article presents a
case study and a
summary of the
literature about the role
of diet in the
management of IC.
Which as the author
admits is limited to
anecdotal reports by
patients and experts.

The author does not
describe her search of
the evidence therefore it
is hard to grade the
strength of her
recommendations.
Based the author’s own
report high quality
evidence to support diet
modifications in IC
appears to be lacking.

treatment (p<0.001),
as did nocturia
(p<0.01) and
frequency (p<0.01).
However, Urgency
was not significantly
improved using this
treatment algorithm
(p=0.09). All domains
of the King’s Health
Questionnaire
showed significant
improvement
(p<0.001) with the
exception of
incontinence impact
(p=0.227).

function and quality of
life cannot be achieved.
Long-term follow-up
and research on the
etiology of IC needs to
be conducted to
determine efficient
therapy.

Data gathered from
patients and experts
on dietary changes
affect on IC
symptoms is
anecdotal. However,
it does show that
eliminating certain
foods does decrease
pain associated with
IC in most patients.
Dietary treatment is
complicated because

There are limited
studies on the effect of
diet on IC. However,
the majority of IC
patients have found
that certain foods can
exacerbate symptoms.
The IC association (ICA)
has created an IC diet
based on anecdotal
information from
patients and urologist.
Foods that are
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(Tettamanti et
al., 2011)

Case control twin
study/ 2-

Female twins with IC
were matched with
healthy twin controls.
Logistical regression
models with a 95%
confidence interval
were used to evaluate
the effect of smoking,
coffee and tea
consumption on
symptoms of IC.

Twin controls were used
to minimize confounding
factors. Disease and
exposure are measured
at the same time;
therefore conclusions
about whether the
exposure preceded or
resulted from the
disease cannot be made.

it must be
individualized and
requires keeping a
food intake and
voiding diary. Foods
should be eliminated
and then
systematically
reintroduced to
determine which are
the offending items.
A concern is that by
eliminating foods or
whole food groups
patients may become
deficient in some
nutrients.
Smoking currently or
formerly and tea
consumption were
associated with
significantly higher
cases of IC symptoms.
Smoking as a risk
factor was
confounded by
familial factors.
Coffee consumption
was not associated
with a higher risk of IC
symptoms.

commonly found to
exacerbate symptoms
include alcoholic
beverages, coffee, tea,
carbonated beverages,
tomatoes, and certain
spices. Diets should be
individualized and
patients should be
careful not to eliminate
too many foods as that
may cause deficiencies
in essential nutrients.

Tea and smoking are
positively associated
with IC but the
association of smoking
with IC is likely to be
confounded by genetic
factors. The
association with tea
consumption is not
confounded by familial
factors. Coffee
consumption does not
have a significant
association with IC
symptoms.

Literature review/4

The methods used to
conduct this literature
review are not
discussed.

Inclusion and exclusion
criteria of articles used
for this review are not
provided. Neither is a
discussion of the
strength of the literature
available. Studies
reviewed are referenced
and described briefly;
comments about the
strength of individual
studies are discussed
briefly. However, the
reader must draw
his/her own conclusion
about the strength of
body of literature
reviewed.

(Unwin, 2011)

Review of literature/
3

The author does not
discuss details of the
literature search
process. However, each
recommendation is
rated based on the

This is a summary of
current literature
without
recommendations made
by the author. Threats
to validity are related to

111

(Theoharides,
2007)

There is no benefit in
the form of pain relief
from the practice of
raising the pH of urine
through diet
modifications or
supplements. Clinical
trials to date have
used adult patients
with varying degrees
of severity of IC
symptoms and
durations of the
disease, making it
difficult to draw
definitive conclusions
about the treatments
studied. Many of the
studies that have
been conducted are
small and the results
should be considered
suggestive not
conclusive.
IC/PBS is considered
in the patient the
otherwise
unexplained pelvic
area pain, urinary
frequency and

There is no curative
treatment available for
IC. Currently the
available literature on
definitive treatment for
IC is lacking.
Intravesical DMSO, oral
amitriptyline, PPS and
hydroxyzine have
variable results. The
most successful
treatment is likely with
a combination of these
treatments.

After establishing
diagnosis PPS is a
baseline treatment
additional multimodal
treatments can be used
as indicated.

strength of the
evidence, for example a
rating of an A is,
“consistent quality
patient oriented
evidence” and C is
based on, “consensus
disease oriented
evidence, usually expert
opinions”

the fact that the method
of literature review is
unavailable.

urgency, diagnosis is
confirmed with
cystoscopy. Oral
therapy with PPS and
amitriptyline and
bladder installation of
DMSO are the
cornerstones of
treatment.

Amitriptyline is safe
and effective for pain
relief. Nonpharmacologic
strategies such as
bladder training, diet
change, counseling,
and physical therapy
may be helpful but
have not been studied
in clinical trials.
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APPENDIX B
Table B.1: SIGN 50 Levels of Evidence
Levels of Evidence
1++

High quality meta-analyses, systematic reviews
of RCTs or RCTs with a very low risk of bias

1+

Well-conducted meta-analyses, systematic
reviews, or RCTs with a low risk of bias

1-

Meta-analysis, systematic reviews, or RCTs
with a high risk of bias

2++

High quality systematic reviews of case control
or cohort studies, high quality case control or
cohort studies with a very low risk of
confounding or bias and a high probability that
the relationship is causal

2+

Well-conducted case control or cohort studies
with a low risk of confounding or bias and
moderate probability that the relationship is
causal.

2-

Case control or cohort studies with a high risk
of confounding or bias and significant risk that
the relationship is not causal

3

Non-analytic studies, example: case reports,
case series

4

Expert opinion

(SIGN, 2011)
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APPENDIX C
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Reproduced with permission from the AUA Interstitial Cystitis (2011). Hanno, P. M., Burks, D. A., Clemens, J. Q., Dmochowski, R. R., Erickson, D. FitzGerald, M. P., Forrest, J. B., Gordon, B.,
Gray, M., Mayer, R. D., Newman, D., Nyberg Jr., L., Payne, C. K., Wesselmann, U., Faraday, M. M.:Guideline on the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome
(2011). American Urological Association Education and Research, Inc., ©2011 http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=ic-bps

Figure C.1: AUA Guideline Algorithm
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APPENDIX D
Table D.1: SIGN 50 Grades of Recommendations
Grade

Explanation

A

At least one meta-analysis, systematic review,
or RCT rated as 1++ and directly applicable to
the target population. Or
A body of evidence consisting principally of
studies rated as 1+, directly applicable to the
target population, and demonstrating overall
consistency of results.

B

A body of evidence including studies rated as
2++ directly applicable to the target population
and demonstrating overall consistency of
results; or Extrapolated evidence from studies
rated as 1++ or 1+

C

A body of evidence including studies rated as
2+, directly applicable to the target population
and demonstrating overall consistency of
results; or Extrapolated evidence from studies
rated as 2++

D

Evidence level 3 or 4; or extrapolated evidence
from studies rated as 2+

(SIGN, 2011)
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